

5 FIELD OF THE INVENTION

The present invention is related to SHB-GAS-102, SHB-GAS-103, and SHB-GAS-104 polypeptides of S. pyogenes (Group A Streptococcus) and corresponding DNA fragments, which may be used to prevent, diagnose and/or treat S. pyogenes infections.

10

BACKGROUND OF THE INVENTION

Streptococci are gram (+) bacteria which are differentiated by group specific carbohydrate antigens A through O which are found at the cell surface. S. pyogenes isolates are further distinguished by type-specific M protein antigens. M proteins are important virulence factors which are highly variable both in molecular weights and in sequences. Indeed, more than 100-M protein types have been identified on the basis of antigenic differences.

20

S. pyogenes is responsible for many diverse infection types, including pharyngitis, erysipelas and impetigo, scarlet fever, and invasive diseases such as bacteremia and necrotizing fasciitis. A resurgence of invasive disease in recent years has been documented in many countries, including those in North America and Europe. Although the organism is sensitive to antibiotics, the high attack rate and rapid onset of sepsis results in high morbidity and mortality.

30 To develop a vaccine that will protect individuals from S. pyogenes infection, efforts have focused on virulence factors such as the type-specific M proteins. However, the carboxy-terminal portion of M proteins was found to induce cross-reactive antibodies which reacted with human myocardium,

tropomyosin, myosin, and vimentin, which might be implicated in autoimmune diseases. Others have used recombinant techniques to produce complex hybrid proteins containing amino-terminal peptides of M proteins from different serotypes. However, a safe vaccine containing all S. pyogenes serotypes will be highly complex to produce and standardize.

In addition to the serotype-specific antigens, other S. pyogenes proteins have generated interest as potential vaccine candidates. The C5a peptidase, which is expressed by at least S. pyogenes 40 serotypes, was shown to be immunogenic in mice, but its capacity to reduce the level of nasopharyngeal colonization was limited. Other investigators have also focused on the streptococcal pyrogenic exotoxins which appear to play an important role in pathogenesis of infection. Immunization with these proteins prevented the deadly symptoms of toxic shock, but did not prevent colonization.

Therefore there remains an unmet need for S. pyogenes antigens that may be used as vaccine components for the prophylaxis and/or therapy of S. pyogenes infection.

SUMMARY OF THE INVENTION

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

According to one aspect, the present invention relates to polypeptides comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

In other aspects, there are provided polypeptides encoded by polynucleotides of the invention, pharmaceutical compositions,

vectors comprising polynucleotides of the invention operably linked to an expression control region, as well as host cells transfected with said vectors and processes for producing polypeptides comprising culturing said host cells under conditions suitable for expression.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 represents the DNA sequence of SHB-GAS-102 gene from serotype M1 S. pyogenes strain ATCC700294; SEQ ID NO: 1.

10 Figure 2 represents the amino acid sequence SHB-GAS-102 polypeptide from serotype M1 S. pyogenes strain ATCC700294; SEQ ID NO: 2.

Figure 3 represents the DNA sequence of SHB-GAS-103 gene from 15 serotype M1 S. pyogenes strain ATCC700294; SEQ ID NO: 3. The underlined portion of the sequence represents the region coding for the leader peptide.

Figure 4 represents the amino acid sequence SHB-GAS-103 20 polypeptide from serotype M1 S. pyogenes strain ATCC700294; SEQ ID NO: 4. The underlined sequence represents the 27 amino acid residues leader peptide.

Figure 5 represents the DNA sequence of SHB-GAS-104 gene from 25 serotype M1 S. pyogenes strain ATCC700294; SEQ ID NO: 5. The underlined sequence represents the region coding for the leader peptide.

Figure 6 represents the amino acid sequence SHB-GAS-104 30 polypeptide from serotype M1 S. pyogenes strain ATCC700294; SEQ ID NO: 6. The underlined sequence represents the 19 amino acid residues leader peptide.

Figure 7 represents the DNA sequence of SHB-GAS-102 gene from serotype M3 S. pyogenes strain MGAS315; SEQ ID NO: 21.

Figure 8 represents the amino acid sequence SHB-GAS-102 protein 5 from M3 S. pyogenes strain MGAS315; SEQ ID NO: 22.

Figure 9 represents the DNA sequence of SHB-GAS-102 gene from serotype M3 S. pyogenes strain SSI-1; SEQ ID NO: 23.

10 Figure 10 represents the amino acid sequence SHB-GAS-102 protein from M3 S. pyogenes strain SSI-1; SEQ ID NO: 24.

Figure 11 represents the DNA sequence of SHB-GAS-102 gene from serotype M5 S. pyogenes strain Manfredo; SEQ ID NO: 25.

15

Figure 12 represents the amino acid sequence SHB-GAS-102 protein from M5 S. pyogenes strain Manfredo; SEQ ID NO: 26.

Figure 13 represents the DNA sequence of SHB-GAS-102 gene from 0 serotype M18 S. pyogenes strain MGAS8232; SEQ ID NO: 27.

Figure 14 represents the amino acid sequence SHB-GAS-102 protein from M18 S. pyogenes strain MGAS8232; SEQ ID NO: 28.

Figure 15 represents the DNA sequence of SHB-GAS-103 gene from serotype M3 S. pyogenes strain MGAS315; SEQ ID NO: 29. The underlined portion of the sequence represents the region coding for the leader peptide.

Figure 16 represents the amino acid sequence SHB-GAS-103 protein from M3 S. pyogenes strain MGAS315; SEQ ID NO: 30. The underlined sequence represents the 27 amino acid residues leader peptide.

Figure 17 represents the DNA sequence of SHB-GAS-103 gene from serotype M3 S. pyogenes strain SSI-1; SEQ ID NO: 31. The underlined portion of the sequence represents the region coding for the leader peptide.

5

Figure 18 represents the amino acid sequence SHB-GAS-103 protein from M3 S. pyogenes strain SSI-1; SEQ ID NO: 32. The underlined sequence represents the 27 amino acid residues leader peptide.

10 Figure 19 represents the DNA sequence of SHB-GAS-103 gene from serotype M5 S. pyogenes strain Manfredo; SEQ ID NO: 33. The underlined portion of the sequence represents the region coding for the leader peptide.

15 Figure 20 represents the amino acid sequence SHB-GAS-103 protein from M5 S. pyogenes strain Manfredo; SEQ ID NO: 34. The underlined sequence represents the 27 amino acid residues leader peptide.

20 Figure 21 represents the DNA sequence of SHB-GAS-103 gene from serotype M18 S. pyogenes strain MGAS8232; SEQ ID NO: 35. The underlined portion of the sequence represents the region coding for the leader peptide.

5 Figure 22 represents the amino acid sequence SHB-GAS-103 protein from M18 S. pyogenes strain MGAS8232; SEQ ID NO: 36. The underlined sequence represents the 27 amino acid residues leader peptide.

10 Figure 23 represents the DNA sequence of SHB-GAS-104 gene from serotype M3 S. pyogenes strain MGAS315; SEQ ID NO: 37. The underlined portion of the sequence represents the region coding for the leader peptide.

Figure 24 represents the amino acid sequence SHB-GAS-104 protein from M3 S. pyogenes strain MGAS315; SEQ ID NO: 38. The underlined sequence represents the 19 amino acid residues leader peptide.

5

Figure 25 represents the DNA sequence of SHB-GAS-104 gene from serotype M3 S. pyogenes strain SSI-1; SEQ ID NO: 39. The underlined portion of the sequence represents the region coding for the leader peptide.

10

Figure 26 represents the amino acid sequence SHB-GAS-104 protein from M3 S. pyogenes strain SSI-1; SEQ ID NO: 40. The underlined sequence represents the 19 amino acid residues leader peptide.

15 Figure 27 represents the DNA sequence of SHB-GAS-104 gene from serotype M5 S. pyogenes strain Manfredo; SEQ ID NO: 41. The underlined portion of the sequence represents the region coding for the leader peptide.

20 Figure 28 represents the amino acid sequence SHB-GAS-104 protein from M5 S. pyogenes strain Manfredo; SEQ ID NO: 42. The underlined sequence represents the 19 amino acid residues leader peptide.

5 Figure 29 represents the DNA sequence of SHB-GAS-104 gene from serotype M18 S. pyogenes strain MGAS8232; SEQ ID NO: 43. The underlined portion of the sequence represents the region coding for the leader peptide.

10 Figure 30 represents the amino acid sequence SHB-GAS-104 protein from M18 S. pyogenes strain MGAS8232; SEQ ID NO: 44. The underlined sequence represents the 19 amino acid residues leader peptide.

Figure 31 depicts the comparison of the nucleotide sequences of the SHB-GAS-102 genes from the S. pyogenes serotype M1 ATCC700294 (SEQ ID NO:1), serotype M3 MGAS315 (SEQ ID NO:21), serotype M3 SSI-1 (SEQ ID NO:23), serotype M5 Manfredo (SEQ ID NO:25) and serotype M18 MGAS8232 (SEQ ID NO:27) strains by using the program Clustal W from NTI sequence analysis software.

Figure 32 depicts the comparison of the predicted amino acid sequences of the SHB-GAS-102 open reading frames from the S. pyogenes serotype M1 ATCC700294 (SEQ ID NO:2), serotype M3 MGAS315 (SEQ ID NO:22), serotype M3 SSI-1 (SEQ ID NO:24), serotype M5 Manfredo (SEQ ID NO:26) and serotype M18 MGAS8232 (SEQ ID NO:28) strains by using the program Clustal W from NTI sequence analysis software.

15

Figure 33 depicts the comparison of the nucleotide sequences of the SHB-GAS-103 genes from the S. pyogenes serotype M1 ATCC700294 (SEQ ID NO:3), serotype M3 MGAS315 (SEQ ID NO:29), serotype M3 SSI-1 (SEQ ID NO:31), serotype M5 Manfredo (SEQ ID NO:33) and serotype M18 MGAS8232 (SEQ ID NO:35) strains by using the program Clustal W from NTI sequence analysis software.

Figure 34 depicts the comparison of the predicted amino acid sequences of the SHB-GAS-103 open reading frames from the S. pyogenes serotype M1 ATCC700294 (SEQ ID NO:4), serotype M3 MGAS315 (SEQ ID NO:30), serotype M3 SSI-1 (SEQ ID NO:32), serotype M5 Manfredo (SEQ ID NO:34) and serotype M18 MGAS8232 (SEQ ID NO:36) strains by using the program Clustal W from NTI sequence analysis software.

Figure 35 depicts the comparison of the nucleotide sequences of the SHB-GAS-104 genes from the S. pyogenes serotype M1 ATCC700294 (SEQ ID NO:5), serotype M3 MGAS315 (SEQ ID NO:37), serotype M3 SSI-1 (SEQ ID NO:39), serotype M5 Manfredo (SEQ ID

NO:41), and serotype M18 MGAS8232 (SEQ ID NO:43) strains by using the program Clustal W from NTI sequence analysis software.

Figure 36 depicts the comparison of the predicted amino acid sequences of the SHB-GAS-104 open reading frames from the S. pyogenes serotype M1 ATCC700294 (SEQ ID NO:6), serotype M3 MGAS315 (SEQ ID NO:38), serotype M3 SSI-1 (SEQ ID NO:40), serotype M5 Manfredo (SEQ ID NO:42) and serotype M18 MGAS8232 (SEQ ID NO:44) strains by using the program Clustal W from NTI sequence analysis software.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides purified and isolated polynucleotides, which encode S. pyogenes polypeptides which may be used to prevent, diagnose and/or treat S. pyogenes infection.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 90% identity to a second polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44.

5

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 98% identity to a second polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44.

10

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 99% identity to a second polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44.

15

According to one aspect, the present invention relates to polypeptides comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

0 According to one aspect, the present invention relates to polypeptides comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44.

According to one aspect, the present invention provides a polynucleotide encoding an epitope bearing portion of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

According to one aspect, the present invention provides a polynucleotide encoding an epitope bearing portion of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44

According to one aspect, the present invention relates to epitope bearing portions of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

5

According to one aspect, the present invention relates to epitope bearing portions of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44.

10 According to one aspect, the present invention provides an isolated polynucleotide comprising a polynucleotide chosen from:

- (a) a polynucleotide encoding a polypeptide having at least 95% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- 15 (b) a polynucleotide encoding a polypeptide having at least 98% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- (c) a polynucleotide encoding a polypeptide having at least 99% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- 20 (d) a polynucleotide encoding a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- (e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- 5 (f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- (g) a polynucleotide comprising SEQ ID No : 1, 3, 5, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43 or fragments or analogs thereof;

- (h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

According to one aspect, the present invention provides an isolated polynucleotide comprising a polynucleotide chosen from:

- (a) a polynucleotide encoding a polypeptide having at least 95% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (b) a polynucleotide encoding a polypeptide having at least 98% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (c) a polynucleotide encoding a polypeptide having at least 99% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (d) a polynucleotide encoding a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (g) a polynucleotide comprising SEQ ID No : 1, 3, 5, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43;
- (h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

According to one aspect, the present invention provides an isolated polynucleotide consisting essentially of a polynucleotide chosen from:

- a) a polynucleotide encoding a polypeptide having at least 95% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30,

32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;

b) a polynucleotide encoding a polypeptide having at least 98% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;

c) a polynucleotide encoding a polypeptide having at least 99% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;

d) a polynucleotide encoding a polypeptide having SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;

e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide having SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;

f) a polynucleotide encoding an epitope bearing portion of a polypeptide having SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;

g) a polynucleotide having SEQ ID No : 1, 3, 5, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43 or fragments or analogs thereof;

h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g) wherein said polynucleotide encodes a polypeptide that is immunogenic.

According to one aspect, the present invention provides an isolated polynucleotide consisting essentially of a polynucleotide chosen from:

- a) a polynucleotide encoding a polypeptide having at least 95% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- 5 b) a polynucleotide encoding a polypeptide having at least 98% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- c) a polynucleotide encoding a polypeptide having at least 99% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- 10 d) a polynucleotide encoding a polypeptide having SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a
- 15 polypeptide having SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- f) a polynucleotide encoding an epitope bearing portion of a polypeptide having SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- 20 g) a polynucleotide having SEQ ID No : 1, 3, 5, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 or 43 ;
- h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g) wherein said polynucleotide encodes a polypeptide that is
- 25 immunogenic.

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

- (a) a polypeptide having at least 95% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- 30 (b) a polypeptide having at least 98% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;

- (c) a polypeptide having at least 99% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- (d) a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- (e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- (f) an epitope bearing portion of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the secretory amino acid sequence is deleted.

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

- (a) a polypeptide having at least 95% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (b) a polypeptide having at least 98% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (c) a polypeptide having at least 99% identity to SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (d) a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- (f) an epitope bearing portion of a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;

- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the secretory amino acid sequence is deleted.

5

According to one aspect, the present invention provides an isolated polypeptide consisting essentially of a polypeptide chosen from:

- 10 a) a polypeptide having at least 95% identity to an amino acid sequence having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- 15 b) a polypeptide having at least 98% identity to an amino acid sequence having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- 20 c) a polypeptide having at least 99% identity to an amino acid sequence having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- d) a polypeptide having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- 5 e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- f) an epitope bearing portion of a polypeptide having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof;
- g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- h) the polypeptide of (a), (b), (c), (d), (e), or (f) wherein the secretory amino acid sequence is deleted

wherein said polypeptide is immunogenic.

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

- 5 a) a polypeptide having at least 95% identity to an amino acid sequence having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- b) a polypeptide having at least 98% identity to an amino acid
10 sequence having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- c) a polypeptide having at least 99% identity to an amino acid sequence having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- d) a polypeptide comprising SEQ ID NO: 2, 4, 6, 22, 24, 26,
15 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide having SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- f) an epitope bearing portion of a polypeptide having SEQ ID
20 NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44;
- g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- h) the polypeptide of (a), (b), (c), (d), (e), or (f) wherein
25 the secretory amino acid sequence is deleted.

Those skilled in the art will appreciate that the invention includes DNA molecules, i.e. polynucleotides and their complementary sequences that encode analogs such as mutants,
0 variants, homologues and derivatives of such polypeptides, as described herein in the present patent application. The invention also includes RNA molecules corresponding to the DNA molecules of the invention. In addition to the DNA and RNA molecules, the invention includes the corresponding polypeptides

and monospecific antibodies that specifically bind to such polypeptides.

In accordance with the present invention, all polynucleotides 5 encoding polypeptides of the present invention are within the scope of the present invention.

In a further embodiment, the polypeptides in accordance with the present invention are antigenic, i.e. are able to bind 10 specifically to components of the immune response, such as antibodies and lymphocytes.

In a further embodiment, the polypeptides in accordance with the present invention are immunogenic or can elicit an immune 15 response in a host.

In a further embodiment, the present invention also relates to polypeptides which are able to raise antibodies having binding specificity to the polypeptides of the present invention as 20 defined above.

An antibody that "has binding specificity" is an antibody that recognizes and binds the selected polypeptide but which does not substantially recognize and bind other molecules in a sample, 5 e.g., a biological sample, which naturally includes the selected peptide. Specific binding can be measured using an ELISA assay in which the selected polypeptide is used as an antigen.

In a further embodiment, the polypeptides in accordance with the present invention can elicit a B cell response in a host.

In a further embodiment, the polypeptides in accordance with the present invention can elicit a T cell response in a host.

In accordance with the present invention, the polypeptides of the invention can also be effective when administered to an host to protect against the bacteria. "Protection" in the biological studies is defined by a significant increase in the survival curve, rate or period. Statistical analysis using the Log rank test to compare survival curves, and Fisher exact test to compare survival rates and numbers of days to death, respectively, can be used to calculate P values and determine whether the difference between the two groups is statistically significant. P values greater than 0.05 are regarded as not significant.

In an additional aspect of the invention there are provided antigenic/immunogenic fragments of the polypeptides of the invention, or of analogs thereof.

The present invention also relates to fragments which are specific to, or for SEQ ID NOS. 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44. A specific fragment contains a defined order of amino acids which occurs in a target polypeptide, and which is characteristic of that target polypeptide, but substantially no other non-target polypeptides. Such polypeptide fragments can be of any size which is necessary to confer specificity, e.g., comprising or consisting of at least 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115 amino acids, etc.

Specific fragments can also be described as being specific for Streptococcus pyogenes, indicating that it occurs in that bacteria, but not in other organisms, especially not in GBS or other bacteria.

The fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such

regions to retain substantially their antigenic/immunogenic properties. Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a polypeptide or analog thereof as described herein.

The present invention further provides fragments having a smaller sequence than the ones described in the figures.

10 The present invention further provides fragments having at least 10 contiguous amino acid residues from the polypeptide sequences of the present invention.

In one embodiment, at least 15 contiguous amino acid residues.

In one embodiment, at least 20 contiguous amino acid residues.

15 In one embodiment, at least 25 contiguous amino acid residues.

In one embodiment, at least 30 contiguous amino acid residues.

In one embodiment, at least 35 contiguous amino acid residues.

In one embodiment, at least 40 contiguous amino acid residues.

In one embodiment, at least 45 contiguous amino acid residues.

20 In one embodiment, at least 50 contiguous amino acid residues.

In one embodiment, at least 55 contiguous amino acid residues.

In one embodiment, at least 60 contiguous amino acid residues.

In one embodiment, at least 65 contiguous amino acid residues.

In one embodiment, at least 70 contiguous amino acid residues.

25 In one embodiment, at least 75 contiguous amino acid residues.

In one embodiment, at least 80 contiguous amino acid residues.

In one embodiment, at least 85 contiguous amino acid residues.

In one embodiment, at least 90 contiguous amino acid residues.

In one embodiment, at least 95 contiguous amino acid residues.

0 In one embodiment, at least 100 contiguous amino acid residues.

In one embodiment, at least 105 contiguous amino acid residues.

In one embodiment, at least 110 contiguous amino acid residues.

In one embodiment, at least 115 contiguous amino acid residues.

- In one embodiment, at least 120 contiguous amino acid residues.
- In one embodiment, at least 125 contiguous amino acid residues.
- In one embodiment, at least 130 contiguous amino acid residues.
- In one embodiment, at least 135 contiguous amino acid residues.
- 5 In one embodiment, at least 140 contiguous amino acid residues.
- In one embodiment, at least 145 contiguous amino acid residues.
- In one embodiment, at least 150 contiguous amino acid residues.
- In one embodiment, at least 155 contiguous amino acid residues.
- In one embodiment, at least 160 contiguous amino acid residues.
- 10 In one embodiment, at least 165 contiguous amino acid residues.
- In one embodiment, at least 170 contiguous amino acid residues.
- In one embodiment, at least 175 contiguous amino acid residues.
- In one embodiment, at least 180 contiguous amino acid residues.
- In one embodiment, at least 185 contiguous amino acid residues.
- 15 In one embodiment, at least 190 contiguous amino acid residues.
- In one embodiment, at least 195 contiguous amino acid residues.
- In one embodiment, at least 200 contiguous amino acid residues.
- In one embodiment, at least 205 contiguous amino acid residues.
- In one embodiment, at least 210 contiguous amino acid residues.
- 20 In one embodiment, at least 215 contiguous amino acid residues.
- In one embodiment, at least 220 contiguous amino acid residues.
- In one embodiment, at least 225 contiguous amino acid residues.
- In one embodiment, at least 230 contiguous amino acid residues.
- In one embodiment, at least 235 contiguous amino acid residues.
- 25 In one embodiment, at least 240 contiguous amino acid residues.
- In one embodiment, at least 245 contiguous amino acid residues.
- In one embodiment, at least 250 contiguous amino acid residues.
- In one embodiment, at least 255 contiguous amino acid residues.
- In one embodiment, at least 260 contiguous amino acid residues.
- 30 In one embodiment, at least 265 contiguous amino acid residues.
- In one embodiment, at least 270 contiguous amino acid residues.
- In one embodiment, at least 275 contiguous amino acid residues.
- In one embodiment, at least 280 contiguous amino acid residues.
- In one embodiment, at least 285 contiguous amino acid residues.

- In one embodiment, at least 290 contiguous amino acid residues.
In one embodiment, at least 295 contiguous amino acid residues.
In one embodiment, at least 300 contiguous amino acid residues.
In one embodiment, at least 305 contiguous amino acid residues.
5 In one embodiment, at least 310 contiguous amino acid residues.
In one embodiment, at least 315 contiguous amino acid residues.
In one embodiment, at least 320 contiguous amino acid residues.
In one embodiment, at least 325 contiguous amino acid residues.
In one embodiment, at least 330 contiguous amino acid residues.
10 In one embodiment, at least 335 contiguous amino acid residues.
In one embodiment, at least 340 contiguous amino acid residues.
In one embodiment, at least 345 contiguous amino acid residues.
In one embodiment, at least 350 contiguous amino acid residues.
In one embodiment, at least 355 contiguous amino acid residues.
15 In one embodiment, at least 360 contiguous amino acid residues.
In one embodiment, at least 365 contiguous amino acid residues.
In one embodiment, at least 370 contiguous amino acid residues.
In one embodiment, at least 375 contiguous amino acid residues.
In one embodiment, at least 380 contiguous amino acid residues.
20 In one embodiment, at least 385 contiguous amino acid residues.
In one embodiment, at least 390 contiguous amino acid residues.
In one embodiment, at least 395 contiguous amino acid residues.
In one embodiment, at least 400 contiguous amino acid residues.
In one embodiment, at least 405 contiguous amino acid residues.
25 In one embodiment, at least 410 contiguous amino acid residues.
In one embodiment, at least 415 contiguous amino acid residues.
In one embodiment, at least 420 contiguous amino acid residues.

Polypeptide fragments of the invention may be of any size that is
0 compatible with the invention. They may range in size from the
smallest specific epitope (e.g., about 6 amino acids) to a nearly
full-length gene product (e.g., a single amino acid shorter than
SEQ ID Nos: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42
or 44).

The skilled person will appreciate that analogs of the polypeptides of the invention will also find use in the context of the present invention, i.e. as antigenic/immunogenic material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the present invention.

As used herein, "fragments", "analogs" or "derivatives" of the polypeptides of the invention include those polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably conserved) and which may be natural or unnatural.

These substitutions are those having a minimal influence on the secondary structure and hydropathic nature of the polypeptide. Preferred substitutions are those known in the art as conserved, i.e. the substituted residues share physical or chemical properties such as hydrophobicity, size, charge or functional groups. These include substitutions such as those described by Dayhoff, M. in Atlas of Protein Sequence and Structure 5, 1978 and by Argos, P. in EMBO J. 8, 779-785, 1989. For example, amino acids, either natural or unnatural, belonging to one of the following groups represent conservative changes:

ala, pro, gly, gln, asn, ser, thr, val;
cys, ser, tyr, thr;
val, ile, leu, met, ala, phe;
lys, arg, orn, his;
and phe, tyr, trp, his.

The preferred substitutions also include substitutions of D-enantiomers for the corresponding L-amino acids.

In one embodiment, preferred base substitutions are located where there is less sequence homology on Figures 31, 33 or 35.

In one embodiment, preferred amino acids substitutions are located where there is less sequence homology on Figures 32, 34 or 36.

5

The additional amino acid residues may be from a heterologous source or may be endogenous to the natural gene.

In an alternative approach, the analogs could be fusion
10 polypeptides, incorporating moieties which render purification easier, for example by effectively tagging the desired polypeptide. It may be necessary to remove the "tag" or it may be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

15

The percentage of homology is defined as the sum of the percentage of identity plus the percentage of similarity or conservation of amino acid type.

20 In one embodiment, analogs of polypeptides of the invention will have about 70% identity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same. In a further embodiment, polypeptides will have greater than 80% identity. In a further embodiment, polypeptides
5 will have greater than 85% identity. In a further embodiment, polypeptides will have greater than 90% identity. In a further embodiment, polypeptides will have greater than 95% identity. In a further embodiment, polypeptides will have greater than 98% identity. In a further embodiment, polypeptides will have
9 greater than 99% identity. In a further embodiment, analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

In one embodiment, analogs of polypeptides of the invention will have about 70% similarity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same. In a further embodiment, polypeptides will have greater than 80% similarity. In a further embodiment, polypeptides will have greater than 85% similarity. In a further embodiment, polypeptides will have greater than 90% similarity. In a further embodiment, polypeptides will have greater than 95% similarity. In a further embodiment, polypeptides will have greater than 98% similarity. In a further embodiment, polypeptides will have greater than 99% similarity. In a further embodiment, analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

15 In one embodiment, analogs of polypeptides of the invention will have about 70% homology with those sequences illustrated in the figures or fragments thereof. In a further embodiment, polypeptides will have greater than 80% homology. In a further embodiment, polypeptides will have greater than 85% homology. In a further embodiment, polypeptides will have greater than 90% homology. In a further embodiment, polypeptides will have greater than 95% homology. In a further embodiment, polypeptides will have greater than 98% homology. In a further embodiment, polypeptides will have greater than 99% homology. In a further embodiment, analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either sequence as appropriate. It is possible to calculate amino acid identity or homology for an optimal alignment. A

program like ELASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are found, each having a different score. Both types of identity analysis are contemplated in the present invention.

In an alternative approach, the analogs or derivatives could be fusion polypeptides, incorporating moieties which render purification easier, for example by effectively tagging the desired protein or polypeptide, it may be necessary to remove the "tag" or it may be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

It is well known that it is possible to screen an antigenic polypeptide to identify epitopic regions, i.e. those regions which are responsible for the polypeptide's antigenicity or immunogenicity. Methods for carrying out such screening are well known in the art. Thus, the fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties.

The invention also encompasses polypeptides having a lower degree of sequence identity, but having sufficient similarity so as to perform one or more of the functions or activities exhibited by the native polypeptides.

Thus, what is important for analogs, derivatives and fragments is that they possess at least a degree of the antigenicity/immunogenicity of the protein or polypeptide from which they are derived.

Also included are polypeptides in which one or more of the amino acid residues includes a substituent group. These polypeptides

include, e.g., modified polypeptides. Known polypeptide modifications include, but are not limited to, glycosylation, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, 5 covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, 10 formylation, gamma carboxylation, glycosylation, GPI anchor formatin, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and 15 ubiquitination.

Such modifications are well-known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, 20 glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in many basic texts, such as *Proteins--Structure and Molecular Properties*, 2nd ed., T.E. Creighton, W.H. Freeman and Company, New York (1993). Many 25 detailed reviews are available on this subject, such as by Wold, F., *Posttranslationail Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al. (1990) *Meth. Enzymol.* 182:626-646 and Rattan et al. (1992) *Ann. N.Y. Acad. Sci.* 663:48-62.

30 Also included are polypeptides which have fused thereto other compounds which alter the polypeptides biological or pharmacological properties i.e. polyethylene glycol (PEG) to increase half-life; leader or secretory amino acid sequences for

ease of purification; prepro- and pro- sequences; and (poly)saccharides.

Furthermore, in those situations where amino acid regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the different epitopes of the different S. pyogenes strains.

Moreover, the polypeptides of the present invention can be modified by terminal -NH₂ acylation (eg. by acetylation, or thioglycolic acid amidation, terminal carboxy amidation, e.g. with ammonia or methylamine) to provide stability, increased hydrophobicity for linking or binding to a support or other molecule.

15

Also contemplated are hetero and homo polypeptide multimers of the polypeptide fragments and analogues. These polymeric forms include, for example, one or more polypeptides that have been cross-linked with cross-linkers such as avidin/biotin, glutaraldehyde or dimethylsuberimidate. Such polymeric forms also include polypeptides containing two or more tandem or inverted contiguous sequences, produced from multicistronic mRNAs generated by recombinant DNA technology.

5 In a further embodiment, the present invention also relates to chimeric polypeptides which comprise one or more polypeptides or fragments or analogs thereof as defined in the figures of the present application.

10 In a further embodiment, the present invention also relates to chimeric polypeptides comprising two or more polypeptides comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof; provided that the polypeptides are linked as to form a chimeric polypeptide.

In a further embodiment, the present invention also relates to chimeric polypeptides comprising two or more polypeptides comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 5 38, 40, 42, 44 provided that the polypeptides are linked as to form a chimeric polypeptide.

Preferably, a fragment, analog or derivative of a polypeptide of the invention will comprise at least one antigenic region i.e. 10 at least one epitope.

In order to achieve the formation of antigenic polymers (i.e. synthetic multimers), polypeptides may be utilized having bishaloacetyl groups, nitroarylhalides, or the like, where the 15 reagents being specific for thio groups. Therefore, the link between two mercapto groups of the different polypeptides may be a single bond or may be composed of a linking group of at least two, typically at least four, and not more than 16, but usually not more than about 14 carbon atoms.

20 In a particular embodiment, polypeptide fragments and analogs of the invention do not contain a starting residue, such as methionine (Met) or valine (Val). Preferably, polypeptides will not incorporate a leader or secretory sequence (signal 25 sequence). The signal portion of a polypeptide of the invention may be determined according to established molecular biological techniques. In general, the polypeptide of interest may be isolated from a S. pyogenes culture and subsequently sequenced to determine the initial residue of the mature protein and 0 therefore the sequence of the mature polypeptide.

It is understood that polypeptides can be produced and/or used without their start codon (methionine or valine) and/or without their leader peptide to favor production and purification of

recombinant polypeptides. It is known that cloning genes without sequences encoding leader peptides will restrict the polypeptides to the cytoplasm of *E. coli* and will facilitate their recovery (Glick, B.R. and Pasternak, J.J. (1998) Manipulation of gene expression in prokaryotes. In "Molecular biotechnology: Principles and applications of recombinant DNA", 2nd edition, ASM Press, Washington DC, p.109-143).

In another embodiment, the polypeptides of the invention may be lacking an N-terminal leader peptide, and/or a transmembrane domain and/or a C-terminal anchor domain.

The present invention further provides a fragment of the polypeptide comprising substantially all of the extra cellular domain of a polypeptide which has at least 70% identity, preferably 80% identity, more preferably 95% identity, to a sequence chosen from SEQ ID NOS: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof, over the entire length of said sequence.

20

According to another aspect of the invention, there are also provided (i) a composition of matter containing a polypeptide of the invention, together with a carrier, diluent or adjuvant; (ii) a pharmaceutical composition comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iii) a vaccine comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iv) a method for inducing an immune response against *S. pyogenes*, in a host, by administering to the host, an immunogenically effective amount of a polypeptide of the invention to elicit an immune response, e.g., a protective immune response to *S. pyogenes*; and particularly, (v) a method for preventing and/or treating a *S. pyogenes* infection, by administering a prophylactic or therapeutic amount of a polypeptide of the invention to a host in need.

According to another aspect of the invention, there are also provided (i) a composition of matter containing a polynucleotide of the invention, together with a carrier, diluent or adjuvant; 5 (ii) a pharmaceutical composition comprising a polynucleotide of the invention and a carrier, diluent or adjuvant; (iii) a method for inducing an immune response against S. pyogenes, in a host, by administering to the host, an immunogenically effective amount of a polynucleotide of the invention to elicit an immune 10 response, e.g., a protective immune response to S. pyogenes; and particularly, (iv) a method for preventing and/or treating a S. pyogenes infection, by administering a prophylactic or therapeutic amount of a polynucleotide of the invention to a host in need.

15 Before immunization, the polypeptides of the invention can also be coupled or conjugated to carrier proteins such as tetanus toxin, diphtheria toxin, hepatitis B virus surface antigen, poliomyelitis virus VP1 antigen or any other viral or bacterial 20 toxin or antigen or any suitable proteins to stimulate the development of a stronger immune response. This coupling or conjugation can be done chemically or genetically. A more detailed description of peptide-carrier conjugation is available in Van Regenmortel, M.H.V., Briand J.P., Muller S., Plaué S., 25 «Synthetic Polypeptides as antigens» in Laboratory Techniques in Biochemistry and Molecular Biology, Vol.19 (ed.) Burdou, R.H. & Van Knippenberg P.H. (1988), Elsevier New York.

According to another aspect, there are provided pharmaceutical 30 compositions comprising one or more S. pyogenes polypeptides or chimeric polypeptides of the invention in a mixture with a pharmaceutically acceptable carrier or diluent.

According to another aspect, there are provided pharmaceutical compositions comprising one or more S. pyogenes polypeptides or chimeric polypeptides of the invention in a mixture with a pharmaceutically acceptable adjuvant. Suitable adjuvants include

5 (1) oil-in-water emulsion formulations such as MF59™, SAF™, Ribit™ ; (2) Freund's complete or incomplete adjuvant; (3) salts i.e. $AlK(SO_4)_2$, $AlNa(SO_4)_2$, $AlNH_4(SO_4)_2$, $Al(OH)_3$, $AlPO_4$, silica, kaolin; (4) saponin derivatives such as Stimulon™ or particles generated therefrom such as ISCOMs (immunostimulating

10 complexes); (5) cytokines such as interleukins, interferons, macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF) ; (6) other substances such as carbon polynucleotides i.e. poly IC and poly AU, detoxified cholera toxin (CTB) and E.coli heat labile toxin for induction of mucosal

15 immunity; and (7) liposomes. A more detailed description of adjuvants is available in a review by M.Z.I Khan et al. in Pharmaceutical Research, vol. 11, No. 1 (1994) pp2-11, and also in another review by Gupta et al., in Vaccine, Vol. 13, No. 14, pp1263-1276 (1995) and in WO 99/24578. Preferred adjuvants

20 include QuilA™, QS21™, Alhydrogel™ and Adjuphos™.

Pharmaceutical compositions of the invention may be administered parenterally by injection, rapid infusion, nasopharyngeal absorption, dermoabsorption, or buccal or oral.

25 The term pharmaceutical composition is also meant to include antibodies. In accordance with the present invention, there is also provided the use of one or more antibodies having binding specificity for the polypeptides of the present invention for

30 the treatment or prophylaxis of streptococcus infection and/or diseases and symptoms mediated by streptococcus infection.

Pharmaceutical compositions of the invention are used for the prophylaxis of S. pyogenes infection and/or diseases and

symptoms mediated by S. pyogenes infection as described in Manual of Clinical Microbiology, P.R. Murray (Ed, in chief), E.J. Baron, M.A. Pfaller, F.C. Tenover and R.H. Tenover. ASM Press, Washington, D.C. seventh edition, 1999, 1773p.

5

In one embodiment, pharmaceutical compositions of the present invention are used for the prophylactic or therapeutic treatment or of many diverse infection types, including pharyngitis, erysipelas and impetigo, scarlet fever, and invasive diseases
10 such as bacteremia and necrotizing fasciitis.

In one embodiment, pharmaceutical compositions of the invention are used for the prophylactic or therapeutic treatment of Streptococcus infection and/or diseases and symptoms mediated by
15 Streptococcus infection, in particular group A Streptococcus (Streptococcus pyogenes), group B Streptococcus (GBS or S. agalactiae), S. pneumoniae, S. dysgalactiae, S. uberis, S. nocardia as well as Staphylococcus aureus.

20 In one embodiment, pharmaceutical compositions of the invention are used for the prophylactic or therapeutic treatment of S. pyogenes infection and/or diseases and symptoms mediated by S. pyogenes infection. In a further embodiment, the S. pyogenes infection is nontypeable S. pyogenes.

25

Pharmaceutical compositions can also be specific or selective for one or more of the mentioned bacteria. For example, a composition can be selective or specific for a group A Streptococcus (Streptococcus pyogenes) and not react with group
30 B Streptococcus (GBS or S. agalactiae), S. pneumoniae, S. dysgalactiae, S. uberis, S. nocardia nor Staphylococcus aureus.

In a further embodiment, the invention provides a method for prophylactic or therapeutic treatment of streptococcus infection

in a host susceptible to streptococcus infection comprising administering to said host a prophylactic or therapeutic amount of a composition of the invention.

5 In a further embodiment, the invention provides a method for prophylactic or therapeutic treatment of S. pyogenes infection in a host susceptible to S. pyogenes infection comprising administering to said host a prophylactic or therapeutic amount of a composition of the invention.

10

As used in the present application, the term "host" includes mammals. In a further embodiment, the mammal is human.

In a particular embodiment, pharmaceutical compositions are administered to those hosts at risk of S. pyogenes infection such as neonates, infants, children, elderly and immunocompromised hosts.

In a particular embodiment, pharmaceutical compositions are administered to those hosts at risk of S. pyogenes infection such as adults.

Pharmaceutical compositions are preferably in unit dosage form of about 0.001 to 100 µg/kg (antigen/body weight) and more preferably 0.01 to 10 µg/kg and most preferably 0.1 to 1 µg/kg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

Pharmaceutical compositions are preferably in unit dosage form of about 0.1 µg to 10 mg and more preferably 1µg to 1 mg and most preferably 10 to 100 µg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

According to another aspect, there are provided polynucleotides encoding polypeptides characterized by the amino acid sequence comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

5

In one embodiment, polynucleotides are those illustrated in SEQ ID No: 1, 3, 5, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43 which may include the open reading frames (ORF), encoding the polypeptides of the invention.

10

Many types of variants of polynucleotides are encompassed by the invention including, e.g., (i) one in which one or more of the nucleotides is substituted with another nucleotide, or which is otherwise mutated; or (ii) one in which one or more of the
15 nucleotides is modified, e.g., includes a substituent group; or (iii) one in which the polynucleotide is fused with another compound, such as a compound to increase the half-life of the polynucleotide; or (iv) one in which additional nucleotides are covalently bound to the polynucleotide, such a sequences encoding
20 a leader or secretory sequence or a sequence which is employed for purification of the polypeptide. The additional nucleotides may be from a heterologous source, or may be endogenous to the natural gene.

25 Polynucleotide variants belonging to type (i) above include, e.g., polymorphisms, including single nucleotide polymorphisms (SNPs), and mutants. Variant polynucleotides can comprise, e.g., one or more additions, insertions, deletions, substitutions, transitions, transversions, inversions, or the like, or any
30 combinations thereof.

Polynucleotide variants belonging to type (ii) above include, e.g., modifications such as the attachment of detectable markers (avidin, biotin, radioactive elements, fluorescent tags and dyes,

energy transfer labels, energy-emitting labels, binding partners, etc.) or moieties which improve expression, uptake, cataloging, tagging, hybridization, detection, and/or stability. The polynucleotides can also be attached to solid supports, e.g., 5 nitrocellulose, magnetic or paramagnetic microspheres (e.g., as described in U.S. Pat. No. 5,411,863; U.S. Pat. No. 5,543,289; for instance, comprising ferromagnetic, supermagnetic, paramagnetic, superparamagnetic, iron oxide and polysaccharide), nylon, agarose, diazotized cellulose, latex solid microspheres, 10 polyacrylamides, etc., according to a desired method. See, e.g., U.S. Pat. Nos. 5,470,967; 5,476,925; 5,478,893.

Polynucleotide variants belonging to type (iii) above are well known in the art and include, e.g., various lengths of polyA⁺ 15 tail, 5'cap structures, and nucleotide analogs, e.g., inosine, thionucleotides, or the like.

Polynucleotide variants belonging to type (iv) above include, e.g., a variety of chimeric, hybrid or fusion polynucleotides. 20 For example, a polynucleotide of the invention can comprise a coding sequence and additional non-naturally occurring or heterologous coding sequence (e.g., sequences coding for leader, signal, secretory, targeting, enzymatic, fluorescent, antibiotic resistance, and other functional or diagnostic peptides); or a 25 coding sequence and non-coding sequences, e.g., untranslated sequences at either a 5' or 3' end, or dispersed in the coding sequence.

It will be appreciated that the polynucleotide sequences 30 illustrated in the figures may be altered with degenerate codons yet still encode the polypeptides of the invention. Accordingly the present invention further provides polynucleotides which hybridize to the polynucleotide sequences herein above described (or the complement sequences thereof) having 70% identity

between sequences. In one embodiment, at least 80% identity between sequences. In one embodiment, at least 85% identity between sequences. In one embodiment, at least 90% identity between sequences. In a further embodiment, polynucleotides are hybridizable under stringent conditions i.e. having at least 95% identity. In a further embodiment, more than 97% identity. In a further embodiment, more than 98% identity. In a further embodiment, more than 99% identity. In a further embodiment, polynucleotides are hybridizable under stringent conditions.

10

Suitable stringent conditions for hybridization can be readily determined by one of skilled in the art (see for example Sambrook et al., (1989) Molecular cloning : A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology, (1999) Edited by Ausubel F.M. et al., John Wiley & Sons, Inc., N.Y.).

"Suitable stringent conditions", as used herein, means, for example, incubating a blot overnight (e.g., at least 12 hours) with a long polynucleotide probe in a hybridization solution containing, e.g., about 5X SSC, 0.5% SDS, 100 µg/ml denatured salmon sperm DNA and 50% formamide, at 42°C. Blots can be washed at high stringency conditions that allow, e.g., for less than 5% bp mismatch (e.g., wash twice in 0.1X SSC and 0.1% SDS for 30 min at 65°C), thereby selecting sequences having, e.g., 95% or greater sequence identity.

Other non-limiting examples of suitable stringent conditions include a final wash at 65°C in aqueous buffer containing 30 mM NaCl and 0.5% SDS. Another example of suitable stringent conditions is hybridization in 7% SDS, 0.5 M NaPO₄, pH 7, 1 mM EDTA at 50°C, e.g., overnight, followed by one or more washes with a 1% SDS solution at 42°C. Whereas high stringency washes can allow for less than 5% mismatch, reduced or low stringency

conditions can permit up to 20% nucleotide mismatch. Hybridization at low stringency can be accomplished as above, but using lower formamide conditions, lower temperatures and/or lower salt concentrations, as well as longer periods of 5 incubation time.

According to another aspect of the invention, there are also provided isolated polynucleotides comprising a sequence that hybridize under stringent conditions to either

- 10 a) a DNA sequence encoding a polypeptide or
b) the complement of a DNA sequence encoding a polypeptide;
wherein said polypeptide comprises SEQ ID NO: 2, 4, 6,
22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or
fragments or analogs thereof.

15 In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
20 (b) the complement of a DNA sequence encoding a
polypeptide;
wherein said polypeptide comprises SEQ ID NO: 2, 4, 6, 22, 24,
26, 28, 30, 32, 34, 36, 38, 40, 42 or 44.

25 According to another aspect of the invention, there are also provided isolated polynucleotides comprising a sequence that hybridize under stringent conditions to either

- a) a DNA sequence encoding a polypeptide or
b) the complement of a DNA sequence encoding a polypeptide;
0 wherein said polypeptide has SEQ ID NO: 2, 4, 6, 22,
24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or
fragments or analogs thereof.

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- 5 (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide has SEQ ID NO: 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44.

10 In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a
- 15 polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID No : 2, 4, 6, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

20 In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- 25 (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID No : 2, 4, 6 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44.

30 In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- a) a DNA sequence encoding a polypeptide or

b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide has at least 10 contiguous amino acid residues from a polypeptide having SEQ ID No : 2, 4, 6, 22, 24, 5 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 or fragments or analogs thereof.

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to 10 either

(a) a DNA sequence encoding a polypeptide or

(b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide has at least 10 contiguous amino acid 15 residues from a polypeptide having SEQ ID No : 2, 4, 6 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 or 44.

In a further embodiment, polynucleotides are those illustrated in SEQ ID NO: 1, 3, 5, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 20 41, 43 or fragments or analogs thereof encoding polypeptides of the invention.

In a further embodiment, polynucleotides are those illustrated in SEQ ID NO: 1, 3, 5, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 25 41, 43 encoding polypeptides of the invention.

As will be readily appreciated by one skilled in the art, polynucleotides include both DNA and RNA.

30 The present invention also includes polynucleotides complementary to the polynucleotides described in the present application.

In a further aspect, polynucleotides encoding polypeptides of the invention, or fragments, analogs or derivatives thereof, may be used in a DNA immunization method. That is, they can be incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo. For example polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is functional in eukaryotic cells. Preferably the vector is injected intramuscularly.

10

According to another aspect, there is provided a process for producing polypeptides of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host cell and recovering the expressed polypeptide product.

Alternatively, the polypeptides can be produced according to established synthetic chemical techniques i.e. solution phase or solid phase synthesis of oligopeptides which are ligated to produce the full polypeptide (block ligation).

General methods for obtention and evaluation of polynucleotides and polypeptides are described in the following references: Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York; PCR Cloning Protocols, from Molecular Cloning to Genetic Engineering, Edited by White B.A., Humana Press, Totowa, New Jersey, 1997, 490 pages; Protein Purification, Principles and Practices, Scopes R.K., Springer-Verlag, New York, 3rd Edition, 1993, 380 pages; Current Protocols in Immunology, Edited by Coligan J.E. et al., John Wiley & Sons Inc., New York.

The present invention provides a vector comprising a polynucleotide of the invention, wherein said DNA is operably linked to an expression control region.

5 The present invention provides a host cell transfected with the vector of the invention.

The present invention provides a process for producing a polypeptide comprising culturing a host cell of the invention
10 under conditions suitable for expression of said polypeptide.

For recombinant production, host cells are transfected with vectors which encode the polypeptides of the invention, and then cultured in a nutrient media modified as appropriate for
15 activating promoters, selecting transformants or amplifying the genes. Suitable vectors are those that are viable and replicable in the chosen host and include chromosomal, non-chromosomal and synthetic DNA sequences e.g. bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations
20 of plasmids and phage DNA. The polypeptide sequence may be incorporated in the vector at the appropriate site using restriction enzymes such that it is operably linked to an expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence), and
25 optionally an operator (control element). One can select individual components of the expression control region that are appropriate for a given host and vector according to established molecular biology principles (Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989;
30 Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York). Suitable promoters include but are not limited to LTR or SV40 promoter, E.coli lac, tac or trp promoters and the phage lambda P_L promoter. Vectors will preferably incorporate an origin of replication as well as

selection markers i.e. ampicillin resistance gene. Suitable bacterial vectors include pET, pQE70, pQE60, pQE-9, pD10 phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 and 5 eukaryotic vectors pBlueBacIII, pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG and pSVL. Host cells may be bacterial i.e. E.coli, Bacillus subtilis, Streptomyces; fungal i.e. Aspergillus niger, Aspergillus nidulins; yeast i.e. Saccharomyces or eukaryotic i.e. CHO, COS.

10

Upon expression of the polypeptide in culture, cells are typically harvested by centrifugation then disrupted by physical or chemical means (if the expressed polypeptide is not secreted into the media) and the resulting crude extract retained to 15 isolate the polypeptide of interest. Purification of the polypeptide from culture media or lysate may be achieved by established techniques depending on the properties of the polypeptide i.e. using ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange 20 chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography. Final purification may be achieved using HPLC.

25 The polypeptides may be expressed with or without a leader or secretion sequence. In the former case the leader may be removed using post-translational processing (see US 4,431,739; US 4,425,437; and US 4,338,397) or be chemically removed subsequent to purifying the expressed polypeptide.

30

According to a further aspect, the S. pyogenes polypeptides of the invention may be used in a diagnostic test for Streptococcus infection, in particular S. pyogenes infection.

Several diagnostic methods are possible, for example detecting S. pyogenes organism in a biological sample, the following procedure may be followed:

- a) obtaining a biological sample from a host;
- 5 b) incubating an antibody or fragment thereof reactive with a S. pyogenes polypeptide of the invention with the biological sample to form a mixture; and
- c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of S.
10 pyogenes.

Alternatively, a method for the detection of antibody specific to a S. pyogenes antigen in a biological sample containing or suspected of containing said antibody may be performed as
15 follows:

- a) obtaining a biological sample from a host;
- b) incubating one or more S. pyogenes polypeptides of the invention or fragments thereof with the biological sample to form a mixture; and
- 20 c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to S. pyogenes.

One of skill in the art will recognize that this diagnostic test
25 may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay or a latex agglutination assay, essentially to determine whether antibodies specific for the polypeptide are present in an organism.

30 The DNA sequences encoding polypeptides of the invention may also be used to design DNA probes for use in detecting the presence of S. pyogenes in a biological sample suspected of

containing such bacteria. The detection method of this invention comprises:

- a) obtaining the biological sample from a host;
- b) incubating one or more DNA probes having a DNA sequence encoding a polypeptide of the invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound DNA probe in the mixture which indicates the presence of S. pyogenes bacteria.

10

The DNA probes of this invention may also be used for detecting circulating S. pyogenes i.e. S. pyogenes nucleic acids in a sample, for example using a polymerase chain reaction, as a method of diagnosing S. pyogenes infections. The probe may be synthesized using conventional techniques and may be immobilized on a solid phase, or may be labelled with a detectable label. A preferred DNA probe for this application is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of the S. pyogenes polypeptides of the invention. In a further embodiment, the preferred DNA probe will be an oligomer having a sequence complementary to at least about 15 contiguous nucleotides of the S. pyogenes polypeptides of the invention. In a further embodiment, the preferred DNA probe will be an oligomer having a sequence complementary to at least about 30 contiguous nucleotides of the S. pyogenes polypeptides of the invention. In a further embodiment, the preferred DNA probe will be an oligomer having a sequence complementary to at least about 50 contiguous nucleotides of the S. pyogenes polypeptides of the invention.

20

Another diagnostic method for the detection of S. pyogenes in a host comprises:

- a) labelling an antibody reactive with a polypeptide of the invention or fragment thereof with a detectable label;

b) administering the labelled antibody or labelled fragment to the host; and

c) detecting specifically bound labelled antibody or labelled fragment in the host which indicates the presence of S. pyogenes.

A further aspect of the invention is the use of the S. pyogenes polypeptides of the invention as immunogens for the production of specific antibodies for the diagnosis and in particular the treatment of S. pyogenes infection. Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively protect against S. pyogenes infection in a test model. One example of an animal model is the mouse model described in the examples herein. The antibody may be a whole antibody or an antigen-binding fragment thereof and may belong to any immunoglobulin class. The antibody or fragment may be of animal origin, specifically of mammalian origin and more specifically of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a recombinant antibody or antibody fragment. The term recombinant antibody or antibody fragment means antibody or antibody fragment which was produced using molecular biology techniques. The antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the S. pyogenes polypeptides but is preferably specific for one.

According to one aspect, the present invention provides the use of an antibody for treatment and/or prophylaxis of S. pyogenes infections.

A further aspect of the invention is the use of the antibodies directed to the polypeptides of the invention for passive

immunization. One could use the antibodies described in the present application.

A further aspect of the invention is a method for immunization, whereby an antibody raised by a polypeptide of the invention is administered to a host in an amount sufficient to provide a passive immunization.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method or system such as direct injection of plasmid DNA into muscles [Wolf et al. H M G (1992) 1: 363; Turnes et al., Vaccine (1999), 17 : 2089; Le et al., Vaccine (2000) 18 : 1893; Alves et al., Vaccine (2001) 19 : 788], injection of plasmid DNA with or without adjuvants [Ulmer et al., Vaccine (1999) 18: 18; MacLaughlin et al., J. Control Release (1998) 56: 259; Hartikka et al., Gene Ther. (2000) 7: 1171-82; Benvenisty and Reshef, PNAS USA (1986) 83:9551; Singh et al., PNAS USA (2000) 97: 811], targeting cells by delivery of DNA complexed with specific carriers [Wa et al., J Biol Chem (1989) 264: 16985; Chaplin et al., Infect. Immun. (1999) 67: 6434], injection of plasmid complexed or encapsulated in various forms of liposomes [Ishii et al., AIDS Research and Human Retroviruses (1997) 13: 142; Perrie et al., Vaccine (2001) 19: 3301], administration of DNA with different methods of bombardment [Tang et al., Nature (1992) 356: 152; Eisenbraun et al., DNA Cell Biol (1993) 12: 791; Chen et al., Vaccine (2001) 19: 2908], and administration of DNA with lived vectors [Tubulekas et al., Gene (1997) 190: 191; Pushko et al., Virology (1997) 239: 389; Spreng et al. FEMS (2000) 27: 299; Dietrich et al., Vaccine (2001) 19: 2506].

In a further embodiment, the invention provides the use of a pharmaceutical composition of the invention in the manufacture

of a medicament for the prophylactic or therapeutic treatment of S. pyogenes infection.

In a further embodiment, the invention provides a kit comprising
5 a polypeptide of the invention for detection or diagnosis of S. pyogenes infection.

Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one
10 of ordinary skill in the art to which this invention belongs.
All publications, patent applications, patents, and other
references mentioned herein are incorporated by reference in
their entirety. In case of conflict, the present specification,
including definitions, will control. In addition, the
15 materials, methods, and examples are illustrative only and not
intended to be limiting.

EXAMPLE 1

This example illustrates the cloning and molecular
20 characteristics of SHB-GAS-102 gene and corresponding
polypeptide

The coding region of S. pyogenes SHB-GAS-102 (SEQ ID NO: 1) gene
was amplified by PCR (Robocycler Gradient 96 Temperature cycler,
25 Stratagene, La Jolla, CA) from genomic DNA of serotype M1 S. pyogenes
strain ATCC700294 using the following oligonucleotide
primers that contained base extensions for the addition of
restriction sites *NdeI* (CATATG) and *XhoI* (CTCGAG): DMAR2174 and
DMAR2175, which are presented in Table 1. PCR products were
30 purified from agarose gel using a QIAquick gel extraction kit
from QIAGEN following the manufacturer's instructions
(Chatsworth, CA), and digested with *NdeI* and *XhoI* (Amersham
Biosciences Inc, Baie d'Urfé, Canada). The pET-19b(+) vector
(Novagen, Madison, WI) was digested with *NdeI* and *XhoI* and

purified from agarose gel using a QIAquick gel extraction kit from QIAGEN (Chatsworth, CA). The *NdeI*-*XhoI* PCR products were ligated to the *NdeI*-*XhoI* pET-19b(+) expression vector. The ligated products were transformed into *E. coli* strain DH5 α 5 [ϕ 80dlacZ Δ M15 Δ (*lacZYA-argF*)U169 *endA1 recA1 hsdR17*(*r_K-m_K*+) *deoR thi-1 supE44 λ -gyrA96 relA1*] (Gibco BRL, Gaithersburg, MD) according to the method of Simanis (Hanahan, D. DNA Cloning, 1985, D.M. Glover (ed), pp. 109-135). Recombinant pET-19b(+) plasmid (rpET19b(+)) containing SHB-GAS-102 gene was purified 10 using the GenElute plasmid kit (Sigma-Aldrich Company Ltd, MO) and DNA insert was sequenced (Taq Dye Deoxy Terminator Cycle Sequencing kit, ABI, Foster City, CA).

15 Table 1. Oligonucleotide primers used for PCR amplifications of *S. pyogenes* genes

Genes	Primers I.D.	Restriction site	Vector	Sequence	DNA modification ¹	SEQ ID NO
SHB-GAS-	DMAR2174	<i>NdeI</i>	PET19b	5' - GAGAAAATACATATG TCACGTATTGGTAAT AAAG-3'	None	7
	DMAR2175	<i>XhoI</i>	PET19b	5' - CCCTCGAGTTATTTA CCTGTTTTACCTTC- 3'	None	8
	DMAR2174 a	<i>BamHI</i>	pCMV-GH	5' - AAGGATCCCATGTCA CGTATTGGTAATAAA G-3'	None	9

Genes	Primers I.D.	Restric- -tion site	Vector	Sequence	DNA modifica- tion ¹	SEQ ID NO
	DMAR2175 a	<i>SalI</i>	pcMV-GH	5' - ACTAGTCGACTTATT TACCTGTTTTACCTT CTTTAAGG-3'	None	10
	DMAR2841 2	n.a.	n.a.	5' - CCTTACAAAGGCAAA GGCATCCGTTACGTT GGTGA-3'	466 - CCTTACAAA GGCAAAGGC ATCCGT -	11
	DMAR2842 2	n.a.	n.a.	5' - TCACCAACGTAACGG ATGCCTTTGCCTTTG TAAGG-3'	489	12
SHB-GAS-103	DMAR1878	<i>NdeI</i>	PET19b	5' - TGTGTGGTTCATATG AGCTACTTGATAATG - 3'	None	13
	DMAR1879	<i>XhoI</i>	PET19b	5' - CCCTCGAGTTAAGGT TTAACAATACTTCC - 3'	None	14
	DMAR1878 a	<i>BamHI</i>	PCMV-GH	5' - GGGGATCCCTTGATA ATGAACCATCAAC - 3'	None	15
	DMAR1879 a	<i>SalI</i>	PCMV-GH	5' - CCGTCGACGGTTTAA CAATACTTCCTAC - 3'	None	16

Genes	Primers I.D.	Restric -tion site	Vector	Sequence	DNA modifica- tion ¹	SEQ ID NO
SHB-GAS-104	DMAR1976	<i>NdeI</i>	PET19b	5' - CTTTTTGGTACATAT GGTGAATCAGCACCC TAA- 3'	None	17
	DMAR1977	<i>XhoI</i>	PET19b	5' - CCCTCGAGTTACGGA TGATCTCCAC- 3'	None	18
	DMAR1976 a	<i>BamHI</i>	pCMV-GH	5' - GCGGATCCGAATCAG CACCTAAAACGG- 3'	None	19
	DMAR1977 a	<i>Sall</i>	pCMV-GH	5' - CCGTCGACGGATGAT CTCCCACGTGGTC- 3'	None	20

¹The underlined amino acid residue represents the modification in the DNA sequence.

² PCR oligonucleotide primer sets used to remove the *BamHI* restriction site present in the SHB-GAS-102 gene.

5

It was determined that the 537-bp including a stop codon (TAA) open reading frame (ORF) of SHB-GAS-102 encodes a 178 amino-acid residues polypeptide with a predicted pI of 9.55 and a predicted molecular mass of 19,431.0 Da. Analysis of the predicted amino acid residues sequence (SEQ ID NO: 2) using the Spscan software (Wisconsin Sequence Analysis Package; Genetics Computer Group) did not reveal the existence of a signal peptide.

To confirm the presence by PCR amplification of SHB-GAS-102 (SEQ ID NO :1) gene, the following 4 serologically distinct S. pyogenes strains were used: the serotype M1 S. pyogenes strain ATCC700294, the serotype M3 S. pyogenes strain ATCC12384, and

the serotype M18 S. pyogenes strain ATCC12357 were obtained from the American Type Culture Collection (Rockville, MD), and the serotype M6 S. pyogenes SPY67 clinical isolate was provided by the Centre de recherche en infectiologie du Centre hospitalier de l'Université Laval, Sainte-Foy, Canada. Chromosomal DNA was isolated from each strain as previously described (Jayarao BM et al. 1991. J. Clin. Microbiol. 29:2774-2778). SHB-GAS-102 (SEQ ID NO :1) gene was amplified by PCR (Robocycler Gradient 96 Temperature cycler) from the genomic DNA purified from the 4 S. pyogenes strains using the oligonucleotide primers DMAR2174 and DMAR2175 (Table 1). PCR was performed with 35 cycles of 45 sec at 95°C, 45 sec at 45°C and 75 sec at 72°C and a final elongation period of 10 min at 72°C. The PCR products were size fractionated in 1% agarose gels and were visualized by ethidium bromide staining. The results of these PCR amplifications are presented in Table 2. The analysis of the amplification products revealed that SHB-GAS-102 (SEQ ID NO :1) gene was present in the genome of all of the 4 S. pyogenes strains tested. These PCR data presented in the previous paragraphs clearly demonstrated that the SHB-GAS-102 gene is highly conserved among streptococcal strains.

Table 2. Identification of S. pyogenes genes by PCR amplification

Strain Identification	Identification by PCR amplification of		
	<u>SHB-GAS-102</u>	<u>SHB-GAS-103</u>	<u>SHB-GAS-104</u>
ATCC700294 (M1)	+	+	+
ATCC12384 (M3)	+	+	+
SPY67 (M6)	+	+	+
ATCC12357 (M18)	+	+	+

In order to evaluate the distribution of the SHB-GAS-102 polypeptide among S. pyogenes isolates, the reactivity of pooled

mouse anti-SHB-GAS-102 sera to a collection of 13 strains of *S. pyogenes* representing 13 M serotypes (Table 3) was tested by immunoblots. These sera were collected from mice immunized three times at two-week intervals with 20 µg of purified recombinant SHB-GAS-102 polypeptides mixed with Quil A adjuvant. The recombinant SHB-GAS-102 polypeptide was produced and purified as described in Example 6. The *S. pyogenes* cells used for this study were prepared following this protocol: bacteria were grown in Todd Hewitt (TH) broth with 0.5% Yeast extract and 1% peptone extract overnight at 37°C in a 8% CO₂ atmosphere. The bacterial suspension was adjusted to an OD_{600nm} of 1.0 and the *S. pyogenes* cells were fixed with 0.3% formaldehyde in PBS buffer for 18 h at 4°C. After incubation, this solution was treated with mutanolysin (7.5U/500µl) for 30 min at 37°C, and boiled for 5 min in SDS-PAGE sample buffer. Antibodies present in the pooled mouse sera recognized the SHB-GAS-102 polypeptide band (≈22 kDa) in all the 13 *S. pyogenes* preparations tested (Table 3). In order to confirm the nature of the polypeptide band, anti-SHB-GAS-102 sera were adsorbed with 12.5 µg of purified recombinant SHB-GAS-102 polypeptides (overnight, 4°C). As expected, this adsorbed sera did not recognize, in the *S. pyogenes* whole-cell extract applied onto the gel, the polypeptide band at ≈22 kDa confirming that this polypeptide band was the SHB-GAS-102 polypeptide.

25

These data as well as the data presented in the previous paragraphs clearly demonstrated that the SHB-GAS-102 gene and the SHB-GAS-102 polypeptide are highly conserved among streptococcal strains.

30

Table 3. Identification of *S. pyogenes* polypeptides by immunoblots with pooled mouse anti-sera raised against recombinant SHB-GAS-102, SHB-GAS-103 and SHB-104 polypeptides¹.

Strain identification (M serotype)	Identification by immunoblot of		
	SHB-GAS-102	SHB-GAS-103	SHB-GAS-104
ATCC700294 (M1)	+	+	+
Spy68 (M2)	+	+	+
ATCC12384 (M3)	+	+	+
Spy71 (M4)	+	+	+
Spy70 (M5)	+	+	+
Spy67 (M6)	+	+	+
Spy88 (M11)	+	+	+
Spy95 (M12)	+	+	+
ATCC12357 (M18)	+	+	+
Spy73 (M22)	+	+	+
Spy91 (M28)	+	+	+
Spy99 (M58)	+	+	+
Spy87 (M77)	+	+	+

¹Sera were collected from mice immunized three times at two-week intervals with 20 µg of purified recombinant polypeptides mixed with Quil A adjuvant. Sera were diluted 1/1000 to perform the immunoblots.

5

EXAMPLE 2

This example illustrates the cloning and molecular characteristics of SHB-GAS-103 gene and corresponding polypeptide

)

The coding region of S. pyogenes SHB-GAS-103 gene (SEQ ID NO: 3) was amplified by PCR (Robocycler Gradient 96 Temperature cycler, Stratagene, LaJolla, Ca) from genomic DNA of serotype M1 S. pyogenes strain ATCC700294 using the following oligos that

contained base extensions for the addition of restriction sites ~~PCT/CA 2004/001510~~ NdeI (CATATG) and XhoI (CTCGAG): DMAR1878 and DMAR1879, which are presented in Table 1. The methods used for cloning SHB-GAS-103 into an expression vector and sequencing are similar to the methods described in Example 1.

It was determined that the 1269-bp including a stop codon (TAA) open reading frame (ORF) of SHB-GAS-103 encodes a 422 amino-acid-residues polypeptide with a predicted pI of 9.11 and a predicted molecular mass of 46,605.3 Da. Analysis of the predicted amino acid residues sequence (SEQ ID NO: 4) using the SpScan software (Wisconsin Sequence Analysis Package; Genetics Computer Group) suggested the existence of a 27 amino acid residues signal peptide (MFQLRKKMTRKQLALLSAGVLTCVVGG).

The SHB-GAS-103 gene was shown to be present after PCR amplification using the oligonucleotide primers DMAR1878 and DMAR1879 in the 4 serologically S. pyogenes strains tested (Table 2). In addition, the SHB-GAS-103 polypeptide was shown to be present in all the 13 S. pyogenes isolates tested by immunoblots as described in Example 1 (Table 3). Indeed, antibodies present in the pooled mouse sera recognized the SHB-GAS-103 polypeptide band (≈ 52 kDa) in all the 13 S. pyogenes preparations tested (Table 3). In order to confirm the nature of the polypeptide band, anti-SHB-GAS-103 sera were adsorbed with 12.5 μ g of purified recombinant SHB-GAS-103 polypeptides (overnight, 4°C). As expected, this adsorbed sera did not recognize, in the S. pyogenes whole-cell extract applied onto the gel, the polypeptide band at ≈ 52 kDa confirming that this polypeptide band was the SHB-GAS-103 polypeptide.

These data presented in the previous paragraphs clearly demonstrated that the SHB-GAS-103 gene and the SHB-GAS-103 polypeptide are highly conserved among streptococcal strains.

EXAMPLE 3

This example illustrates the cloning and molecular characteristics of SHB-GAS-104 gene and corresponding polypeptide

The coding region of S. pyogenes SHB-GAS-104 gene (SEQ ID NO: 5) was amplified by PCR (Robocycler Gradient 96 Temperature cycler, Stratagene, LaJolla, Ca) from genomic DNA of serotype M1 S. pyogenes strain ATCC700294 using the following oligos that contained base extensions for the addition of restriction sites NdeI (CATATG) and XhoI (CTCGAG): DMAR1976 and DMAR1977, which are presented in Table 1. The methods used for cloning SHB-GAS-104 into an expression vector and sequencing are similar to the methods described in Example 1.

It was determined that the 885-bp including a stop codon (TAA) open reading frame (ORF) of SHB-GAS-104 encodes a 294 amino-acid-residues polypeptide with a predicted pI of 5.83 and a predicted molecular mass of 33,381.9 Da. Analysis of the predicted amino acid residues sequence (SEQ ID NO: 6) using the Spscan software (Wisconsin Sequence Analysis Package; Genetics Computer Group) suggested the existence of a 19 amino acid residues signal peptide (MIKRCKGIGLALMAFFLVA).

The SHB-GAS-104 gene was shown to be present after PCR amplification using the oligonucleotide primers DMAR1976 and DMAR1977 in the 4 serologically S. pyogenes strains tested (Table 2). The methods used for PCR amplification of the SHB-GAS-104 gene were similar to the methods presented in Example 1.

In addition, the distribution of the SHB-GAS-104 polypeptide among S. pyogenes isolates have been evaluated as described in Example 1 using a S. pyogenes extract prepared by the following method: bacteria were grown in TH broth with 0.5% Yeast extract

and 1% peptone extract overnight at 37°C in a 8% CO₂ atmosphere. The bacterial suspension was adjusted to an OD_{600nm} of 0.8. After centrifugation, the bacterial pellet was resuspended in 500 µl of extraction buffer (0.1 M Tris-HCl pH 7.6) and pelleted by 5 centrifugation. The pellet was frozen for 10 min at - 80°C and thawed at 37°C for 5 min. The freeze-thaw cycle was repeated three times. Bacterial pellet was resuspended in 500 µl of extraction buffer and sonicated 8 x 15 sec. Samples were centrifuged (14 000 X g) at 4°C for 15 min and supernatant was 10 boiled for 5 min in SDS-PAGE sample buffer. Antibodies present in the pooled mouse anti-SHB-GAS-104 sera recognized the SHB-GAS-104 polypeptide band (≈37.5 kDa) in all of the 13 S. pyogenes preparations tested (Table 3). In order to confirm the nature of the polypeptide band, anti-SHB-GAS-104 sera were 15 adsorbed with 12.5 µg of purified recombinant SHB-GAS-104 polypeptide (overnight, 4°C). As expected, this adsorbed serum did not recognize, in the S. pyogenes extract applied onto the gel, the polypeptide band at ≈37.5 kDa confirming that this polypeptide band was the SHB-GAS-104 polypeptide.

20

These PCR data presented in the previous paragraphs clearly demonstrated that the SHB-GAS-104 gene is highly conserved among streptococcal strains.

25 EXAMPLE 4

This example illustrates the cloning of S. pyogenes genes in CMV plasmid pCMV-GH.

The DNA coding regions of S. pyogenes polypeptides were inserted 30 in phase downstream of a human growth hormone (hGH) gene which was under the transcriptional control of the cytomegalovirus (CMV) promotor in the plasmid vector pCMV-GH (Tang et al., Nature, 1992, 356 :152). The CMV promotor is a non functional plasmid in E. coli cells but active upon administration of the

plasmid in eukaryotic cells. The vector also incorporated the ampicillin resistance gene.

In order to remove the *Bam*HI site into the SHB-GAS-102 gene, 5 mutagenesis experiments using the Quickchange Site-Directed Mutagenesis kit from Stratagene were performed according to the manufacturer's recommendations. The oligonucleotides DMAR2841 and DMAR2842 (Table 1) and the SHB-GAS-102 gene cloned into pET vector as DNA template were used to perform the mutagenesis 0 experiments. The modification on the SHB-GAS-102 gene generated by site-directed mutagenesis is presented in the Table 1.

The coding regions of modified SHB-GAS-102, SHB-GAS-103 (SEQ ID NO: 3), and SHB-GAS-104 (SEQ ID NO: 5) genes were amplified by 5 PCR (Robocycler Gradient 96 Temperature cycler, Stratagene, LaJolla, Ca) from pET vector containing the modified SHB-GAS-102 gene or the genomic DNA of serotype M1 *S. pyogenes* strain ATCC700294 (for SHB-GAS-103 and SHB-GAS-104 genes) using oligonucleotide primers that contained base extensions for the 10 addition of restriction sites *Bam*HI (GGATCC) and *Sal*I (GTCGAC) which are described in Table 1. The PCR products were purified from agarose gel using a QIAquick gel extraction kit from QIAGEN (Chatsworth, CA) and digested with restriction enzymes (Amersham Biosciences Inc, Baie d'Urfé, Canada). The pCMV-GH vector 15 (Laboratory of Dr. Stephen A. Johnston, Department of Biochemistry, The University of Texas, Dallas, Texas) was digested with *Bam*HI and *Sal*I and purified from agarose gel using the QIAquick gel extraction kit from QIAGEN (Chatsworth, CA). The *Bam*HI-*Sal*I DNA fragments were ligated to the *Bam*HI-*Sal*I 20 pCMV-GH vector to create the hGH-SHB-GAS-102, hGH-SHB-GAS-103, and hGH-SHB-GAS-104 fusion polypeptides under the control of the CMV promoter. The ligated products were transformed into *E. coli* strain DH5 α [ϕ 80d*lacZ* Δ M15 Δ (*lacZ*YA-*argF*)U169 *endA*1 *recA*1 *hsdR*17(*r_K-m_K*+) *deoR* *thi*-1 *supE*44 λ ⁻*gyrA*96 *relA*1] (Gibco BRL,

Gaithersburg, MD) according to the method of Simanis (Hanahan, D. DNA Cloning, 1985, D.M. Glover (ed), pp. 109-135). The recombinant pCMV plasmids were purified using the GenElute plasmid kit (Sigma-Aldrich company Ltd, MO) and the nucleotide sequences of the DNA inserts were verified by DNA sequencing.

EXAMPLE 5

This example illustrates the use of DNA to elicit an immune response to S. pyogenes polypeptide antigens.

0 Groups of 8 female BALB/c mice (Charles River, St-Constant, Québec, Canada) were immunized by intramuscular injection of 100 µl three times at two- or three-week intervals with 50 µg of recombinant pCMV-GH encoding modified SHB-GAS-102, SHB-GAS-103 5 (SEQ ID NO: 3), and SHB-GAS-104 (SEQ ID NO: 5) genes in presence of 50 µg of granulocyte-macrophage colony-stimulating factor (GM-CSF)- expressing plasmid pCMV-GH-GM-CSF (Laboratory of Dr. Stephen A. Johnston, Department of Biochemistry, The University of Texas, Dallas, Texas). As control, groups of mice were 10 injected with 50 µg of pCMV-GH in presence of 50 µg of pCMV-GH-GM-CSF. Blood samples were collected from the orbital sinus prior to each immunization and seven days following the third injection and serum antibody responses were determined by ELISA using the corresponding His-tagged labeled S. pyogenes 25 recombinant polypeptides as coating antigens. The production and purification of these His-tagged labeled S. pyogenes recombinant polypeptides are presented in Example 6.

EXAMPLE 6

30 This example illustrates the production and purification of S. pyogenes recombinant polypeptides.

The recombinant pET-19b(+) plasmids with SHB-GAS-102 (SEQ ID NO: 1), SHB-GAS-103 (SEQ ID NO: 3), and SHB-GAS-104 (SEQ ID NO: 5)

genes were used to transform by electroporation (Gene Pulser II apparatus, BIO-RAD Labs, Mississauga, Canada) E. coli strains BL21 (DE3) (F⁻ompT hsdS_B (r_B⁻m_B⁻) gal dcm (DE3)) or BL21 star (DE3) (F⁻ompT hsdS_B (r_B⁻m_B⁻) gal dcm rne131 (DE3)) (Novagen, 5 Madison, WI). In these strains of E. coli, the T7 promotor controlling expression of the recombinant polypeptide is specifically recognized by the T7 RNA polymerase (present on the λDE3 prophage) whose gene is under the control of the lac promotor which is inducible by isopropyl-β-d-thio-10 galactopyranoside (IPTG). The transformants BL21(DE3)/rpET or BL21 star (Des)/rpET were grown at 37°C with agitation at 250 rpm in LB broth (peptone 10g/L, yeast extract 5g/L, NaCl 10g/L) containing 100 µg of carbenicillin (Sigma-Aldrich Canada Ltd., Oakville, Canada) per ml until the A₆₀₀ reached a value of 0.6. 15 In order to induce the production of His-tagged S. pyogenes recombinant polypeptides, the cells were incubated for 2 additional hours in the presence of IPTG at a final concentration of 1 mM. Induced cells from a 500 ml culture were pelleted by centrifugation and frozen at -70°C.

20

The purification of the recombinant polypeptides from the soluble fraction of IPTG-induced BL21(DE3)/rpET19b(+) or BL21 star(DE3)/rpET19b(+) was done by affinity chromatography based on the properties of the His-Tag sequence (10 consecutive 25 histidine residues) to bind to divalent cations (Ni²⁺) immobilized on the His-Bind metal chelation resin. Briefly, the pelleted cells obtained from a 400 mL culture induced with IPTG was resuspended in lysis buffer (20 mM Tris, 500 mM NaCl, 10 mM imidazole, pH 7.9), sonicated and centrifuged at 12,000 X g for 30 20 min to remove debris. The supernatant was incubated with Ni-NTA agarose resin (QIAGEN) for 45 min at 4°C. The S. pyogenes recombinant polypeptides were eluted from the resin with a solution of 250 mM imidazole-500mM NaCl-20 mM Tris, pH 7.9. The removal of the salt and imidazole from the samples was done by

dialysis against PBS buffer overnight at 4°C. The amount of recombinant polypeptide was estimated by MicroBCA (Pierce, Rockford, Ill.).

5 EXAMPLE 7

This example illustrates the accessibility to antibodies of the S. pyogenes recombinant polypeptides at the surface of intact streptococcal cells.

0 Bacteria were grown in Todd Hewitt (TH) broth (Difco Laboratories, Detroit, MI) with 0.5% Yeast extract (Difco Laboratories) and 1% peptone extract (Merck, Darmstadt, Germany) at 37°C in a 8% CO₂ atmosphere to give an OD_{600nm} of 0.600 (~10⁹ CFU/ml). Dilutions of anti-SHB-GAS-102, anti-SHB-GAS-103, anti-
5 SHB-GAS-104, or control sera were then added and allowed to bind to the cells, which were incubated for 2 h at 4°C. Samples were washed 2 times in blocking buffer [phosphate-buffered saline (PBS) containing 2% bovine serum albumin (BSA)], and then 0.5 ml of goat fluorescein (FITC)-conjugated anti-mouse IgG + IgM
10 diluted in blocking buffer was added. After an additional incubation of 60 min at room temperature, samples were washed 2 times in blocking buffer and fixed with 0.3 % formaldehyde in PBS buffer for 18-24 h at 4°C. Cells were kept in the dark at 4°C until analyzed by flow cytometry (Epics® XL; Beckman
15 Coulter, Inc.). Ten thousands intact S. pyogenes cells were analyzed per sample.

EXAMPLE 8

This example illustrates the protection against fatal S.
30 pyogenes infection induced by passive immunization of mice with rabbit hyper-immune sera.

New Zealand rabbit (Charles River) was immunized subcutaneously three times at 3-week intervals at multiple sites with 100 µg of

His-tagged recombinant SHB-GAS-102 protein in the presence of Freund's incomplete adjuvant (Gibco-BRL). Blood samples were collected three weeks after the third injection. The antibodies present in the serum were partially purified by precipitation using 40% saturated ammonium sulfate solution. Groups of 6 female Balb/c mice (Charles River) were injected intravenously with 500 µl of partially purified serum collected from a rabbit immunized with the recombinant SHB-GAS-102 protein, or a rabbit immunized with an unrelated control recombinant protein. Eighteen hours later the mice were challenged with approximately 2×10^7 CFU of the type 3 S. pyogenes strain ATCC12384. Samples of the S. pyogenes challenge inoculum were plated on blood agar plates to determine the CFU and to verify the challenge dose. Deaths were recorded for a period of 8 days.

15

As presented in Table 4, 67% (4/6) mice immunized with partially purified serum collected from rabbit immunized with the recombinant SHB-GAS-102 protein were protected against a lethal challenge. On the contrary, immunization of mice with serum collected from rabbit immunized with an irrelevant protein did not confer such protection (Table 4).

20

Table 4. Ability of SHB-GAS-102-specific antibodies to elicit passive protection against S. pyogenes strain ATCC12384 (M3)

Group	No. mice surviving	% survival
SHB-GAS-102-specific antibodies	4/6	67 %
Unrelated protein-specific antibodies	0/6	0 %

25

EXAMPLE 9

This example illustrates the protection of mice against fatal S. pyogenes infection induced by immunization with recombinant polypeptides.

5

Groups of female Balb/c mice (Charles River) were immunized subcutaneously three times at two-week intervals with 20 µg of affinity purified SHB-GAS-102, SHB-GAS-103, or SHB-GAS-104 His-tagged recombinant polypeptides in presence of 10 µg of QuilA
10 adjuvant (Cedarlane Laboratories Ltd, Hornby, Canada) or, as control, with QuilA adjuvant alone in PBS or with 20 µg of irrelevant polypeptide in presence of QuilA. Blood samples were collected from the orbital sinus on day 1, 14 and 28 prior to each immunization and 14 days (day 42) following the third
15 injection. One week later the mice were challenged with approximately $4-8 \times 10^6$ CFU of the type 3 S. pyogenes strain ATCC12384. Samples of the S. pyogenes challenge inoculum were plated on blood agar plates to determine the CFU and to verify the challenge dose. Deaths were recorded for a period of 7
20 days.

As presented in Table 5, more than 83% (10/12) mice immunized with SHB-GAS-102 polypeptide were protected against a lethal challenge. Mice immunized with SHB-GAS-103 and SHB-GAS-104 were
25 also protected against a lethal challenge (7/12). On the contrary, immunization of mice with adjuvant only or with an irrelevant protein did not confer such protection (Table 5).

Table 5. Ability of recombinant SHB-GAS-102, SHB-GAS-103, and
30 SHB-GAS-104 polypeptides to elicit protection against S. pyogenes strain ATCC12384 (M3)

<u>Groups</u>	<u>No. mice surviving</u>	<u>% survival</u>
20µg of SHB-GAS-102 polypeptide + 10µg of QuilA	10/12	83

<u>Groups</u>	<u>No. mice surviving</u>	<u>% survival</u>
20µg of SHB-GAS-103 polypeptide + 10µg of QuilA	7/12	58
20µg of SHB-GAS-104 polypeptide + 10µg of QuilA	7/12	58
20µg of irrelevant polypeptide + 10µg of QuilA	2/12	17
10 µg of QuilA in PBS	3/12	25

Figure 1

```

1 atgtcacgta ttggaataaa agtaattact atgcctgcag gcgttgaatt aacaaataac
61 aacaatgtta ttactgttaa aggccctaaa ggcgaactca ctcgtgagtt caacaaaaat
121 attgaaatca aagttgaagg gactgaaatc acagttgtac gtcctaacga ctcaaaagaa
181 atgaaaacaa tccatggtac aaccctggtt aacttgaata acatggttgt aggtgtttct
241 gaaggtttca aaaaagatct tgaaatgaag ggtgtcgggt accgtgctca acttcaaggt
301 actaaacttg tcctttcagt aggtaaatct caccaagacg aagttgaagc tccagaagga
361 attactttca ctgttgctaa cccaacttca atctcagttg aaggaatcaa caaagaagtt
421 gttggtcaaa cagctgctta catccgtagc ttgcgttcac cagagcctta caaaggcaaa
481 gggatccggt acgttggtga atacgtacgc cttaaagaag gtaaacagg taaataa

```

(SEQ ID NO: 1)

Figure 2

```

1 MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI TVVRPNDSKE
61 MKTIHGTTTR NLNNMVVGVS EGFKKDLEMK VGGYRAQLQG TKLVLSVGKS HQDEVEAPEG
121 ITFTVANPTS ISVEGINKEV VGQTAAYIRS LRSPEPYK GK GIRYVGEYVR LKEGKTGK

```

(SEQ ID NO: 2)

Figure 3

```

1 atgtttcagt taagaaaaaa aatgacqcg c aaacaattag ccttggtgag tgctggaagt
61 ttgacctgtg tggttgggtg tagctacttg ataatagaacc atcaacaaca agaaattgtc
121 tctagtgtca acaaaagtaaa agccttaacc ataaaagaag ccatggaaca aggaaaagat
181 atcagcttga ccttagctgg cgaagtaaca gctaacaaca gcagcaaggt caaatcgac
241 tcaagtaaa gagaagtcaa agaggtcttt gttaaaaaag gcgatgttgt caaagtagga
301 caacccttgt ttagctatga aacgtcacag cggttaacgg ctcaaagttc agaatttgat
361 gttcaaacca aagccaatca gtcctaaagt gctaaaacca atgcagcatt gaagtgggaa
421 acctacaatc gcaagggtcaa tgaaatcaac accctaaaat ctgctacaa cactgcacca
481 gatgagagct tactagagca aattcgacgc gcagaagaca gtgtatcca agcactaagc
541 gatgccaaaa cagcagatag cgatgtcaaa accgctcaaa tcgaactcga taaagctaata
601 gctactgccca caacggaaaa aggtaaacta gagtatgaca ccgttaagtc agacaccgca
661 ggaaccattg ttagtctaaa tactgatttg ccaaatcaat caaaatccaa aaaagaaaat
721 gaaactttta tgaaaattat cgacaaatca aaaatgtag tcaaaggtaa cattagttaa
781 tttgaccgtg acaagttaaa aatcggtcaa aaagtcgaag tgattgaccg caaagacaac
841 tctaaaaaat ggactggaaa agtaacccaa gttggcaacc tcaaagcaga ggaagaggc
901 caaggtcaag gccaagggtg caatgaccaa caagataatc caaaccaagc aaaattccct
961 tatgttattg aacttgacca atcagacaag cagccactca ttggctcaca cacctatgtt
1021 aatgtgctca acaatgttcc agaagctggc aagatcgat tgaaagaaac ctttacaatg
1081 gcagaaaatg gaaaaacctg tgtgtggaaa gttgataaaa acaaggtcaa aaaacaagaa
1141 atcaagacta agcccttctc aaaagggtat gttgaggtaa caagtggctt gactatgcaa
1201 gataagattg ctgagccgct tcctggcatg aaagacggtg tggaggtagg aagtattgtt
1261 aaaccttaa

```

(SEQ ID NO: 3)

Figure 4

```

1 MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEIV SSVNKKV KALT IKEAMEQKGD
61 ISLTLAGEVT ANNSSKVKID SSKGEVKEVF VKKGDVVKVG QPLFSYETSQ RLTAQSSEFD
121 VQTKANQLQV AKTNAALKWE TYNRKVNEIN TLKSRYNAP DESLLEQIRS AEDSVSQALS
181 DAKTADSDVK TAQIELDKAN ATATTEKGL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN
241 ETFMEIIDKS KMLVKGNISE FDRDKLKIGQ KVEVIDRKN SKKWTGKVTO VGNLKAEEKG
301 QGQGQGGNDQ QDNPNQAKFP YVIELDQSDK QPLIGSHTYV NVLNNVPEAG KIVLKETFTM
361 AENGKTYVWK VDKNKVKKQE IKTKPFSKGY VEVTSGLTMQ DKIAQPLPGM KDGMEVGSIV
421 KP

```

(SEQ ID NO: 4)

Figure 5

```

1 atgataaaac gatgtaaagg aattgggtcta gccttaaatgg ccttcttttt ggtagcttgt
61 gtgaatcagc accctaaaac ggctaaagag actgaacagc agagaattgt agccacttcg
121 gttgctgtgg ttgatatctg tgaccgttta aatttagacc tcgttggggg ttgtgatagt
181 aaattatata cccttcctaa acgctatgat gctgttaagc gtgtgggttt acccatgaat
241 cctgatatag agttgattgc ttctttgaaa ccaacttgga ttttgagtcc caattcttta
301 caagaagatt tggaaaccaa gtatcaaaaa ttggatactg agtatgggtt tttgaactta
361 cgaagtgttg agggcatgta ccagtcatt gatgatttag ggaacctttt ccaacgtcaa
421 caagaagcaa aagaattgcg ccagcaatac caggactatt atcgtgcttt ccaagctaaa
481 cgtaagggga agaaaaagcc taaagtgcct attcttatgg gcttgccagg tagttatttg
541 gtggcgacga accaatctta tgtagggaat cttttggact tggcaggtgg tgagaatgtt
601 tatcagtcag atgagaaaaga atttctatca gctaatacctg aagacatgct ggctaaggag
661 cctgacttga ttttacgaac agctcatgcc attccagaca aggtaaaagt gatgtttgac
721 aaagaatttg ctgaaaatga tatttggaag cattttacgg cagtcaagga agggaaagtc
781 tatgatttgg acaataccct gtttggcatg agtgctaaat tgaactaccc agaagccttg
841 gacaccttaa cacagctttt tgaccacgtg ggagatcatc cgtaa

```

(SEQ ID NO: 5)

Figure 6

```

1 MIKRCKGIGL ALMAFFLVAC VNQHPKTAKE TEQQRIVATS VAVVDICDRL NLDLVGVCDs
61 KLYTLPKRYD AVKRVGLPMN PDIELIASLK PTWILSPNSL QEDLEPKYQK LDTEYGFLNL
121 RSVEGMYQSI DDLGNLFQRO QEAKELRQOY QDYRYAFQAK RKGKKKPKVL ILMGLPGSYL
181 VATNQSYVGN LLDLAGGENV YQSDEKEFLS ANPEDMLAKE PDLILRTAHA IPDKVKVMFD
241 KEFAENDIWK HFTAVKEGKV YDLNNTLFGM SAKLNYPEAL DTLTQLFDHV GDHP

```

(SEQ ID NO: 6)

Figure 7

```

1 atgtcacgta ttggttaataa agtaattact atgcctgcag gcgttgaatt aacaaataac
61 aacaatgtta ttactgttaa aggccctaaa ggcgaactca ctcgtgagtt taacaaaaat
121 attgaaatca aagttgaagg gactgaaatc acagttgtac gtcctaacga ctcaaaagaa
181 atgaaaacaa tccatggtag aaccctgtgt aacttgaata acatggttgt aggtgtttct
241 gaaggtttca aaaaagatct tgaaatgaag ggtgtcgggt accgtgctca acttcaaggt
301 actaaacttg tcctttcagt aggtaaatct caccaagacg aagttgaagc tcagaagga
361 attactttca ctgttgctaa cccaacttca atctcagttg aaggaatcaa caaagaagtt
421 gttggtcaaa cagctgctta catccgtagc ttgcgttcac cagagcctta caaaggcaaa
481 gggatccgtt acgttgggtga atacgtacgc cttaaagaag gtaaaacagg taaataa

```

(SEQ ID NO: 21)

Figure 8

```

1 MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI TVVRPNDSKE
61 MKTIHGTTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG TKLVLSVGKS HQDEVEAPEG
121 ITFTVANPTS ISVEGINKEV VGQTAAAYIRS LRSPEPYKGK GIRYVGEYVR LKEGKTGK

```

(SEQ ID NO: 22)

Figure 9

```

1 atgtcacgta ttggtataaa agtaattact atgcctgcag gcgttgaatt aacaaataac
61 aacaatgtta ttactgttaa aggccctaaa ggcgaactca ctctgtgagtt taacaaaaaat
121 attgaaatca aagttgaagg gactgaaatc acagttgtac gtcctaacga ctcaaaagaa
181 atgaaaacaa tccatggtac aaccctgct aacttgaata acatggttgt aggtgtttct
241 gaaggtttca aaaaagatct tgaaatgaag ggtgtcggtt accgtgctca acttcaaggt
301 actaaacttg tcctttcagt aggtaaatct caccaagacg aagttgaagc tccagaagga
361 attactttca ctgttgctaa cccaacttca atctcagttg aaggaatcaa caaagaagtt
421 gttggtcaaa cagctgctta catccgtagc ttgcgttcac cagagcctta caaaggcaaa
481 gggatccggt acgttggtga atacgtacgc cttaaagaag gtaaaacagg taaataa

```

(SEQ ID NO: 23)

Figure 10

```

1 MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI TVVRPNDKE
61 MKTIHGTTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG TKLVLSVGKS HQDEVEAPEG
121 ITFTVANPTS ISVEGINKEV VGQTAAYIRS LRSPEPYKGK GIRYVGEYVR LKEGKTGK

```

(SEQ ID NO: 24)

Figure 11

```

1 atgtcacgta ttggtataaa agtaattact atgcctgcag gcgttgaatt aacaaataac
61 aacaatgtta ttactgttaa aggccctaaa ggcgaactca ctctgtgagtt caacaaaaaat
121 attgaaatca aagttgaagg gactgaaatc acagttgtac gtcctaacga ctcaaaagaa
181 atgaaaacaa tccatgggac aaccctgct aacttgaata acatggttgt aggtgtttct
241 gaaggtttca aaaaagatct tgaaatgaag ggtgtcggtt accgcgctca acttcaaggt
301 actaaacttg tcctttcagt aggtaaatct caccaagacg aagttgaagc tccagaagga
361 attactttca ctgttgctaa cccaacttca atctcagttg aaggaatcaa caaagaagtt
421 gttggtcaaa cagctgctta catccgtagc ttgcgttcac cagagcctta caaaggcaaa
481 gggatccggt acgttggtga atacgtacgc cttaaagaag gtaaaacagg taaataa

```

(SEQ ID NO: 25)

Figure 12

```

1 MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI TVVRPNDKE
61 MKTIHGTTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG TKLVLSVGKS HQDEVEAPEG
121 ITFTVANPTS ISVEGINKEV VGQTAAYIRS LRSPEPYKGK GIRYVGEYVR LKEGKTGK

```

(SEQ ID NO: 26)

Figure 13

```

1 atgtcacgta ttggtataaa agtaattact atgcctgcag gtgttgaatt aacaaataac
61 aacaatgtta ttactgttaa aggccctaaa ggcgaactca ctctgtgagtt caacaaaaaat
121 attgaaatca aagttgaagg gactgaaatc acagttgtac gtcctaacga ctcaaaagaa
181 atgaaaacaa tccatggtac aaccctgct aacttgaata acatggttgt aggtgtttct
241 gaaggtttca aaaaagatct tgaaatgaag ggtgtcggtt accgtgctca acttcaaggt
301 actaaacttg tcctttcagt aggtaaatct caccaagacg aagttgaagc tccagaagga
361 attactttca ctgttgctaa cccaacttca atctcagttg aaggaatcaa caaagaagtt
421 gttggtcaaa cagctgctta catccgtagc ttgcgttcac cagagcctta caaaggcaaa
481 gggatccggt acgttggtga atacgtacgc cttaaagaag gtaaaacagg taaataa

```

(SEQ ID NO: 27)

Figure 14

1 MSRI GNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI TVVRPNDSKE
 61 MKTIHGTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG TKLVLSVGKS HQDEVEAPEG
 121 JTFTVANPTS ISVEGINKEV VGQTAAYIRS LRSPEPYK GK GIRYVGEYVR LKEGKTGK
 (SEQ ID NO: 28)

Figure 15

1 atgtttcagt taagaaaaaa aatgacgcgc aaacaattag ccttggtgag tgctggagtg
 61 ttgacctgtg tggttggtgg tagctacttg ataatgaacc atcaacaaca agaaattgtc
 121 tctagtgtca acaaagttaa agccttaacc ataaaagaag ccatggaaca aggaaaagat
 181 atcagcttga ccttagctgg cgaagtaaca gctaacaaca gcagcaaagt caaatcgac
 241 tcaagtaaa gagaagtcaa agaggtcttt gttaaaaaag gcgatgttgt caaagtagga
 301 caacccttgt ttagctatga aacgtcacag cggttaacgg ctcaaagttc agaatttgat
 361 gttcaaacca aagccaatca gtcceaagtt gctaaaacca atgcagcatt gaagtgggaa
 421 acctacaatc gcaaggtcaa tgaaatcaac accctaaaat ctgcgtacaa cactgcacca
 481 gatgagagct tactagagca aattcgcagc gcagaagaca gtgtatccca agcactaagc
 541 gatgccaaaa cagcagatag cgatgtcaaa accgctcaaa tcgaactcga taaagctaata
 601 gctactgcca caacggaaaa aggtaaacta gagtatgaca ccgttaagtc agacaccgca
 661 ggaaccattg ttagtctaaa tactgatttg ccaaatcaat caaatccaa aaaagaaaat
 721 gaaactttta tggaatttat cgacaaatca aaaatgtag tcaaaggtaa cattagttaa
 781 tttgaccgtg acaagttaaa aatcggtcaa aaagtcgaag tgattgaccg caaagacaac
 841 tctaaaaaat ggactggaaa agtaacccaa gttggcaacc tcaaagcaga gaaaaaggc
 901 caaggtcaag gccaaggtgg caatgaccaa caagataatc caaaccaagc aaaattccct
 961 tatgttattg aacttgacca atcagacaag cagccactca ttggctcaca cacctatgtt
 1021 aatgtactca acaatgttcc agaagctggc aagatcgtat tgaaagaaac ctttacaatg
 1081 gcagaaaatg gaaaaaccta tgtgtggaaa gttgataaaa acaaggtcaa aaaacaagaa
 1141 atcaagacta agcccttctc aaaaggttat gttgaggtaa caagtggctt gactatgcaa
 1201 gataagattg ctacagccgt tcttggcatg aaagacggta tggaggtagg aagtattgtt
 1261 aaaccttaa
 (SEQ ID NO: 29)

Figure 16

1 MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEIV SSVNKVKALT IKEAMEQGKD
 61 ISLTLAGEVT ANNSSKVKID SSKGEVKEVF VKKGDVVKVG QPLFSYETSQ RLTAQSSEFD
 121 VQTKANQLQV AKTNAALKWE TYNRKVNEIN TLKSRyntAP DESLLEQIRS AEDSVSQALS
 181 DAKTADSDVK TAQIELDKAN ATATTEKGL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN
 241 ETFMEIIDKS KMLVKGNISE FDRDKLKIGQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG
 301 QGQGQGGNDQ QDNPNQAKFP YVIELDQSDK QPLIGSHTYV NVLNNVPEAG KIVLKETFMT
 361 AENGKTYVWK VDKNKVKKQE IKTKPFPSKY VEVTSGLTMQ DKIAQPLPGM KDGMEVGSIV
 421 KP
 (SEQ ID NO: 30)

Figure 17

1 atgtttcagt taagaaaaaa aatgacgcgc aaacaattag ccttggtgag tgctggagtg
 61 ttgacctgtg tggttggtgg tagctacttg ataatgaacc atcaacaaca agaaattgtc
 121 tctagtgtca acaaagttaa agccttaacc ataaaagaag ccatggaaca aggaaaagat
 181 atcagcttga ccttagctgg cgaagtaaca gctaacaaca gcagcaaagt caaatcgac
 241 tcaagtaaa gagaagtcaa agaggtcttt gttaaaaaag gcgatgttgt caaagtagga
 301 caacccttgt ttagctatga aacgtcacag cggttaacgg ctcaaagttc agaatttgat
 361 gttcaaacca aagccaatca gtcceaagtt gctaaaacca atgcagcatt gaagtgggaa
 421 acctacaatc gcaaggtcaa tgaaatcaac accctaaaat ctgcgtacaa cactgcacca
 481 gatgagagct tactagagca aattcgcagc gcagaagaca gtgtatccca agcactaagc
 541 gatgccaaaa cagcagatag cgatgtcaaa accgctcaaa tcgaactcga taaagctaata
 601 gctactgcca caacggaaaa aggtaaacta gagtatgaca ccgttaagtc agacaccgca

Figure 17 (continued)

```

661 ggaaccattg ttagtctaaa tactgatttg ccaaataaat caaaatccaa aaaagaaaat
721 gaaactttta tggaaattat cgacaaatca aaaatgtag tcaaaggtaa cattagttaa
781 tttagaccgtg acaagttaaa aatcggtcaa aaagtcgaag tgattgaccg caaagacaac
841 tctaaaaaat ggactggaaa agtaacccaa gttggcaacc tcaaagcaga ggaaaaaggc
901 caaggtcaag gccaaagggtg caatgacca caagataatc caaaccaagc aaaattccct
961 tatgttattg aacttgacca atcagacaag cagccactca ttggctcaca cacctatgtt
1021 aatgtactca acaatgttcc agaagctggc aagatcgtat tgaaagaaac ctttacaatg
1081 gcagaaaaatg gaaaaaccta tgtgtggaaa gttgataaaa acaaggtcaa aaaacaagaa
1141 atcaagacta agcccttctc aaaaggttat gttgaggtaa caagtggctt gactatgcaa
1201 gataagattg cttagccgct tcctggcatg aaagacggta tggaggtagg aagtattgtt
1261 aaaccttaa

```

(SEQ ID NO: 31)

Figure 18

```

1 MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEIV SSVNKKV KALT IKEAMEQKGD
61 ISLTLAGEV ANNSSKVKID SSKGEVKEVF VKKGDVVKVG QPLFSYETSQ RLTAQSSEFD
121 VQTKANQLQV AKTNAALKWE TYNRKVNEIN TLKSRYNTAP DESLLEQIRS AEDSVSQALS
181 DAKTADSDVK TAQIELDKAN ATATTEKGL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN
241 ETFMEIIDKS KMLVKGNISE FDRDKLKIGQ KVEVIDRKN SKKWTGKVTQ VGNLKAEEKG
301 QGQGQGGNDQ QDNPNQAKFP YVIELDQSDK QPLIGSHTYV NVLNNVPEAG KIVLKETFTM
361 AENGKTYVWK VDKNKVKKQE IKTKPFSKGY VEVTSGLTMO DKIAQPLPGM KDGMEVGSIV
421 KP

```

(SEQ ID NO: 32)

Figure 19

```

1 atgtttcagt taagaaaaaa aatgacgcgc aaacaattag ccttqttqag tgctggagtg
61 ttgacctgtg tggttggtgg tagctacttg ataatgaacc atcaacaaca agaagttgtc
121 tctagtgtca acaaagtaaa agccttaacc ataaaagaag ccatggaaca aggaagaagat
181 atcagcttga ccttagctgg cgaagtaaca gctaacaaca gcagcaaatg caaatcgac
241 tcaagtaaa gagaagtcaa agaggtcttt gtcaaaaaag gcgatgttgt caaagtagga
301 caacccttgt ttagctatga aacgtcacag cggttaacgg ctcaaagttc agaatttgat
361 gttcaaacca aagccaatca actccaagtt gctaaaacea atgcagcatt gaagtgggaa
421 acctacaatc gcaagggtcaa tgaaatcaac accctaaaaat ctgctacaa cactgacca
481 gatgagagct tactagagca aattcgacgc gcagaagaca gtgtatccca agcactaagc
541 gatgccaaaa cagcagatag cgatgtcaaa accgctcaa tcgaactcga taaagctaata
601 gctactgcca caatggaaaa aggtaaacta gagtatgaca ccgttaagtc agacaccgca
661 ggaaccattg ttagcctaaa tactgatttg ccaaataaat caaaatccaa aaaagaaaat
721 gaaactttta tggaaattat cgacaaatca aaaatgtag tcaaaggtaa catcagttaa
781 tttagaccgtg acaagttaaa aatcgatcaa aaagtcgaag tgattgaccg caaagacaac
841 tctaaaaaat ggactggaaa agtaacccaa gttggcaacc tcaaagcaga ggaaaaaggc
901 caaggtcaag gccaaagggtg caatgacca caagacaatc caaaccaagc aaaattccct
961 tatgttatcg aacttgacca atcagacaag cagccactca ttggctcaca cacctatgtt
1021 aatgtgctca acaatgttcc agaagctggc aagatcgtat tgaaagaaac ctttacaatg
1081 gcagaaaaatg gaaaaaccta tgtgtggaaa gttgataaaa acaaggtcaa aaaacaagaa
1141 atcaagacta agcccttctc aaaaggttat gttgagggtg caagtggctt gactatgcaa
1201 gataagattg cttagccgct tcctggcatg aaagacggta tggaggtagg aagtattgtt
1261 aaaccttaa

```

SEQ ID NO: 33

Figure 20

```

1 MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEVV SSVNKVKALT IKEAMEQGKD
61 ISLTLAGEVT ANNSSKVKID SSKGEVKEVF VKKGDVVKVG QPLFSYETSQ RLTAQSSEFD
121 VQTKANQLQV AKTNAALKWE TYNRKVNEIN TLKSRYNTAP DESLLEQIRS AEDSVSQALS
181 DAKTADSDVK TAQIELDKAN ATATMEKGKL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN
241 ETFMEIIDKS KMLVKGNISE FDRDKLKIDQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG
301 QGQGQGGNDQ QDNPNQAKFP YVIELDQSDK QPLIGSHTYV NVLNNVPEAG KIVLKETFMT
361 AENGKTYVWK VDKNKVKKQE IKTKPFSKGY VEVTSGLTMQ DKIAQPLPGM KDGMEVGSIV
421 KP

```

(SEQ ID NO: 34)

Figure 21

```

1 atgtttcagt taagaaaaaa aatgacqccq aaacaattag ccttggtgag tgctggagtg
61 ttgacctgtg tggttggtgg tacctacttg ataatgaatc atcaacaaca agaaattgtc
121 tctagtgtca acaaagtaaa agccttaacc ataaaagaag ccattggaaca aggaaaagat
181 atcagcttga ccttagctgg cgaagtaaca gctaacaaca gcagcaaatg caaaatcgac
241 tcaagtaaaag gagaagtcaa agatgtcttt gtcaaaaaag gcgatgttgt caaagtagga
301 caacccttgt ttagctatga aacgtcacaa cgggttaacgg ctcaaagttc agaatttgat
361 gttcaaacca aagccaatca actccaagtt gctaaaacca atgcagcatt gaagtgggaa
421 acctacaatc gcaaggtcaa tgaaatcaat accctaaaat ctcgctacaa cactgcacca
481 gatgagagct tactagagca aattcgcagc gcagaagaca gtgtatctca agcactaagc
541 gatgccaaaa cagcagatag cgatgtcaaa accgctcaaa tcgaactcga taaagctaata
601 gctactgccg caacggaaaa aggtaaacta gagtatgaca ccgttaagtc agacaccgca
661 ggaaccattg ttagtctaaa tactgatttg ccaaatacaat caaaatccaa aaaagaaaaat
721 gaaactttta tggaaattat cgacaaatca aaaatgtag tcaaaggtaa catcagttaa
781 tttgaccgtg acaagttaaa aatcgatcaa aaagtccaag tgattgaccg caaagacaac
841 tctaaaaaat ggactggaaa agtaacccaa gttggcaacc tcaaagcaga ggaaaaaggc
901 caaggtcaag gccaaaggtg caatgaccaa caagataatc caaaccaagc aaaattccct
961 tatgttatcg aacttgacca atcagacaag cagccactca ttggttcaca cacctatggt
1021 aatgtgtctca acaatgttcc agaagctggc aagatcgtat tgaaagaaac ctttacaatg
1081 gcagaaaaatg gaaaaaccta tgtgtggaaa gttgataaaa acaaggtcaa aaaacaagaa
1141 atcaagacta agcccttctc aaaaggttat gttgaggtga caagcggctt gactatgcaa
1201 gataagattg ctgagccgct tcctggcatg aaagacggtg tggaggtagg aagtattggt
1261 aaaccttaa

```

(SEQ ID NO: 35)

Figure 22

```

1 MFQLRKKMTR KQLALLSAGV LTCVVGGTYL IMNHQQQEVV SSVNKVKALT IKEAMEQGKD
61 ISLTLAGEVT ANNSSKVKID SSKGEVKDFV VKKGDVVKVG QPLFSYETSQ RLTAQSSEFD
121 VQTKANQLQV AKTNAALKWE TYNRKVNEIN TLKSRYNTAP DESLLEQIRS AEDSVSQALS
181 DAKTADSDVK TAQIELDKAN ATAATEKGKL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN
241 ETFMEIIDKS KMLVKGNISE FDRDKLKIDQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG
301 QGQGQGGNDQ QDNPNQAKFP YVIELDQSDK QPLIGSHTYV NVLNNVPEAG KIVLKETFMT
361 AENGKTYVWK VDKNKVKKQE IKTKPFSKGY VEVTSGLTMQ DKIAQPLPGM KDGMEVGSIV
421 KP

```

(SEQ ID NO: 36)

Figure 23

```

1 atgataaaac gatgtaaagg aattgggtcta gtcttaaatgg ccttcctttt ggtagcttgt
61 gtaaatcagc accctaaaac ggctaaagag actgaacagc agagaattgt agccacttcg
121 gttgctgtgg ttgatatctg tgaccgttta aatttagacc tcggtggggg ttgtgatagt
181 aaattatata cccttcctaa acgctatgat gctgttaagc gtgtggggtt acccatgaat
241 cctgatatag agttgattgc ttctttgaaa ccaacttggg ttttgagtc caattcttta
301 caagaagatt tggaacccaa gtatcaaaaa ttggatactg agtatgggtt tttgaactta
361 cgaagtgttg agggcatgta ccagtctatt gatgatttag ggaacctttt ccaacgtcaa
421 caagaagcaa aagaattgag ccagcaatac caggactatt atcgtgcttt ccaagctaaa
481 cgcaagggga agaaaaagcc taaagtgctt attcttatgg gcttgccagg tagttatttg
541 gtggcgacga accaatctta tgtaggggaat cttttggact tggcagggtg tgagaatggt
601 tatcagtcag atgagaaaga atttctatca gttaatcctg aagacatgct agctaaggag
661 cctgacttga ttttacgaac agctcacgcc attccagaca aggtaaaagt gatgtttgac
721 aaagaatttg ctgaaaatga tatttggaaa cattttacgg cagtcaagga agggaaagtc
781 tatgatttgg acaataccct gtttggcatg agtgctaaat tgaactaccc agaagccttg
841 gacaccttaa cacagctttt tgaccacgtg ggagatcatc cgtaa

```

(SEQ ID NO: 37)

Figure 24

```

1 MIKRCKGIGL VLMAFFLVAC VNQHPKTAKE TEQQRIVATS VAVVDICDRL NLDLVGVCDL
61 KLYTLPKRYD AVKRVGLPMN PDIELIASLK PTWILSPNSL QEDLEPKYQK LDTEYGFLNL
121 RSVEGMYQSI DDLGNLFQRQ QEAKELRQY QDYRAFAQAK RKGKKKPKVL ILMGLPGSYL
181 VATNQSIVGN LLDLAGGENV YQSDKEFLS VNPEDMLAKE PDLILRTAHA IPDKVKVMFD
241 KEFAENDIWK HFTAVKEGKV YLDNLTFLGM SAKLNYPEAL DTLTQLFDHV GDHP

```

(SEQ ID NO: 38)

Figure 25

```

1 atgataaaac gatgtaaagg aattgggtcta gtcttaaatgg ccttcctttt ggtagcttgt
61 gtaaatcagc accctaaaac ggctaaagag actgaacagc agagaattgt agccacttcg
121 gttgctgtgg ttgatatctg tgaccgttta aatttagacc tcggtggggg ttgtgatagt
181 aaattatata cccttcctaa acgctatgat gctgttaagc gtgtggggtt acccatgaat
241 cctgatatag agttgattgc ttctttgaaa ccaacttggg ttttgagtc caattcttta
301 caagaagatt tggaacccaa gtatcaaaaa ttggatactg agtatgggtt tttgaactta
361 cgaagtgttg agggcatgta ccagtctatt gatgatttag ggaacctttt ccaacgtcaa
421 caagaagcaa aagaattgag ccagcaatac caggactatt atcgtgcttt ccaagctaaa
481 cgcaagggga agaaaaagcc taaagtgctt attcttatgg gcttgccagg tagttatttg
541 gtggcgacga accaatctta tgtaggggaat cttttggact tggcagggtg tgagaatggt
601 tatcagtcag atgagaaaga atttctatca gttaatcctg aagacatgct agctaaggag
661 cctgacttga ttttacgaac agctcacgcc attccagaca aggtaaaagt gatgtttgac
721 aaagaatttg ctgaaaatga tatttggaaa cattttacgg cagtcaagga agggaaagtc
781 tatgatttgg acaataccct gtttggcatg agtgctaaat tgaactaccc agaagccttg
841 gacaccttaa cacagctttt tgaccacgtg ggagatcatc cgtaa

```

(SEQ ID NO: 39)

Figure 26

```

1 MIKRCKGIGL VLMAFFLVAC VNQHPKTAKE TEQQRIVATS VAVVDICDRL NLDLVGVCDL
61 KLYTLPKRYD AVKRVGLPMN PDIELIASLK PTWILSPNSL QEDLEPKYQK LDTEYGFLNL
121 RSVEGMYQSI DDLGNLFQRQ QEAKELRQY QDYRAFAQAK RKGKKKPKVL ILMGLPGSYL
181 VATNQSIVGN LLDLAGGENV YQSDKEFLS VNPEDMLAKE PDLILRTAHA IPDKVKVMFD
241 KEFAENDIWK HFTAVKEGKV YLDNLTFLGM SAKLNYPEAL DTLTQLFDHV GDHP

```

(SEQ ID NO: 40)

Figure 27

```

1 atgataaaac gatgtaaagg aattggtcta qccttaatgg ccttcttttt ggtagcttgt
61 gtgaatcagc accctaaaac ggctaaagag actgaacagc agagaattgt agccacttcg
121 gttgctgtgg ttgatattctg tgaccgttta aatttagacc tcgttggggg ttgtgatagt
181 aaattatata cccttcctaa acgctatgat gctgttaagc gtgtggggtt acccatgaat
241 cctgatatag agttgattgc ttctttgaaa ccaacttga ttttgagtcc caattcttta
301 caagaagatt tggaaaccaa gtatcaaaaa ttggatactg agtatggttt tttgaactta
361 cgaagtgttg agggcatgta ccagtcatt gatgatttag ggaacctttt ccaacgtcaa
421 caagaagcaa aagaattgcg ccagcaatac caggactatt atcgtgcttt ccaagctaaa
481 cgtaagggga agaaaaagcc taaagtgcct attcttatgg gcttgccagg tagttatttg
541 gtggcgacga accaatctta ttaggggaat cttttggatt tggcaggtgg tgagaatgtt
601 tatcagtcag atgagaaaga atttctatca gctaactctg aagacatgct ggctaaggag
661 cctgatttga ttttacgaac agctcacgcc attccagaca aggtaaaagt gatgtttgac
721 aaagaatttg ctgaaaatga tatttgaaa cattttacgg cagtcaagga agggaaagtc
781 tatgatttgg acaataccct gtttggcatg agtgctaaat tgaactacc agaagccttg
841 gacaccttaa cacagctttt tgaccgcgtg ggagatcatc cgtaa

```

(SEQ ID NO: 41)

Figure 28

```

1 MIKRCKGIGL ALMAFFLVAC VNQHPKTAKE TEQQRIVATS VAVVDICDRL NLDLVGVCDL
61 KLYTLPKRYD AVKRVGLPMN PDIELIASLK PTWILSPNSL QEDLEPKYQK LDTEYGFLNL
121 RSVEGMYQSI DDLGNLFQRQ QEAKELRQY QDYRAFQAK RKGKKKPKVL ILMGLPGSYL
181 VATNQSYVGN LLDLAGGENV YQSDKEFLS ANPEDMLAKE PDLILRTAHA IPDKVKVMFD
241 KEFAENDIWK HFTAVKEGKV YDLNNTLFGM SAKLNYPEAL DTLTQLFDRV GDHP

```

(SEQ ID NO: 42)

Figure 29

```

1 atgataaaac gatgtaaagg aattggtcta qtcttaatgg ccttcttttt ggtagcttgt
61 gtaaatcagc accctaaaac ggctaaagag actgaacagc agagaattgt agccacttcg
121 gttgctgtgg ttgatattctg tgaccgttta aatttagacc tcgttggggg ttgtgatagt
181 aaattatata cccttcctaa acgctatgat gctgttaagc gtgtggggtt acccatgaat
241 cctgatatag agttgattgc ttctttgaaa ccaacttga ttttgagtcc caattcttta
301 caagaagatt tggaaaccaa gtatcaaaaa ttggatactg agtatggttt tttgaactta
361 cgaagtgttg agggcatgta ccagtcatt gatgatttag ggaacctttt ccaacgtcaa
421 caagaagcaa aagaattgcg ccagcaatac caggactatt atcgtgcttt ccaagctaaa
481 cgtaagggga agaaaaagcc taaagtgcct attcttatgg gcttgccagg tagttatttg
541 gtggcgacga accaatctta ttaggggaat cttttggact tggcaggtgg tgagaatgtt
601 tatcagtcag atgagaaaga atttctatca gtaactctg aagacatgct agctaaggag
661 cctgacttga ttttacgaac agctcacgcc attccagaca aggtaaaagt gatgtttgac
721 aaagaatttg ctgaaaatga tatttgaaa cattttacgg cagtcaagga agggaaagtc
781 tatgatttgg acaataccct gtttggcatg agtgctaaat tgaactacc agaagccttg
841 gacaccttaa cacagctttt tgaccacgtg ggagatcatc cgtaa

```

(SEQ ID NO: 43)

Figure 30

```

1 MIKRCKGIGL VLMAFFLVAC VNQHPKTAKE TEQQRIVATS VAVVDICDRL NLDLVGVCDL
61 KLYTLPKRYD AVKRVGLPMN PDIELIASLK PTWILSPNSL QEDLEPKYQK LDTEYGFLNL
121 RSVEGMYQSI DDLGNLFQRQ QEAKELRQY QDYRAFQAK RKGKKKPKVL ILMGLPGSYL
181 VATNQSYVGN LLDLAGGENV YQSDKEFLS VNPEDMLAKE PDLILRTAHA IPDKVKVMFD
241 KEFAENDIWK HFTAVKEGKV YDLNNTLFGM SAKLNYPEAL DTLTQLFDHV GDHP

```

(SEQ ID NO: 44)

Figure 31

	1		50
ATCC700294	ATGTCACGTA TTGGTAATAA AGTAATTACT ATGCCTGCAG GCGTTGAATT		
MGAS315	ATGTCACGTA TTGGTAATAA AGTAATTACT ATGCCTGCAG GCGTTGAATT		
SSI-1	ATGTCACGTA TTGGTAATAA AGTAATTACT ATGCCTGCAG GCGTTGAATT		
Manfredo	ATGTCACGTA TTGGTAATAA AGTAATTACT ATGCCTGCAG GCGTTGAATT		
MGAS8232	ATGTCACGTA TTGGTAATAA AGTAATTACT ATGCCTGCAG GTGTTGAATT		
	51		100
ATCC700294	AACAAATAAC AACAAATGTTA TTACTGTTAA AGGCCCTAAA GGCGAACTCA		
MGAS315	AACAAATAAC AACAAATGTTA TTACTGTTAA AGGCCCTAAA GGCGAACTCA		
SSI-1	AACAAATAAC AACAAATGTTA TTACTGTTAA AGGCCCTAAA GGCGAACTCA		
Manfredo	AACAAATAAC AACAAATGTTA TTACTGTTAA AGGCCCTAAA GGCGAACTCA		
MGAS8232	AACAAATAAC AACAAATGTTA TTACTGTTAA AGGCCCTAAA GGCGAACTCA		
	101		150
ATCC700294	CTCGTGAGTT CAACAAAAAT ATTGAAATCA AAGTTGAAGG GACTGAAATC		
MGAS315	CTCGTGAGTT TAACAAAAAT ATTGAAATCA AAGTTGAAGG GACTGAAATC		
SSI-1	CTCGTGAGTT TAACAAAAAT ATTGAAATCA AAGTTGAAGG GACTGAAATC		
Manfredo	CTCGTGAGTT CAACAAAAAT ATTGAAATCA AAGTTGAAGG GACTGAAATC		
MGAS8232	CTCGTGAGTT CAACAAAAAT ATTGAAATCA AAGTTGAAGG GACTGAAATC		
	151		200
ATCC700294	ACAGTTGTAC GTCCTAACGA CTCAAAAGAA ATGAAAACAA TCCATGGTAC		
MGAS315	ACAGTTGTAC GTCCTAACGA CTCAAAAGAA ATGAAAACAA TCCATGGTAC		
SSI-1	ACAGTTGTAC GTCCTAACGA CTCAAAAGAA ATGAAAACAA TCCATGGTAC		
Manfredo	ACAGTTGTAC GTCCTAACGA CTCAAAAGAA ATGAAAACAA TCCATGGGAC		
MGAS8232	ACAGTTGTAC GTCCTAACGA CTCAAAAGAA ATGAAAACAA TCCATGGTAC		
	201		250
ATCC700294	AACCCGTGCT AACTTGAATA ACATGGTTGT AGGTGTTTCT GAAGGTTTCA		
MGAS315	AACCCGTGCT AACTTGAATA ACATGGTTGT AGGTGTTTCT GAAGGTTTCA		
SSI-1	AACCCGTGCT AACTTGAATA ACATGGTTGT AGGTGTTTCT GAAGGTTTCA		
Manfredo	AACCCGTGCT AACTTGAATA ACATGGTTGT AGGTGTTTCT GAAGGTTTCA		
MGAS8232	AACCCGTGCT AACTTGAATA ACATGGTTGT AGGTGTTTCT GAAGGTTTCA		
	251		300
ATCC700294	AAAAAGATCT TGAAATGAAG GGTGTCGGTT ACCGTGCTCA ACTTCAAGGT		
MGAS315	AAAAAGATCT TGAAATGAAG GGTGTCGGTT ACCGTGCTCA ACTTCAAGGT		
SSI-1	AAAAAGATCT TGAAATGAAG GGTGTCGGTT ACCGTGCTCA ACTTCAAGGT		
Manfredo	AAAAAGATCT TGAAATGAAG GGTGTCGGTT ACCGCGCTCA ACTTCAAGGT		
MGAS8232	AAAAAGATCT TGAAATGAAG GGTGTCGGTT ACCGTGCTCA ACTTCAAGGT		
	301		350
ATCC700294	ACTAAACTTG TCCTTTTCAGT AGGTAAATCT CACCAAGACG AAGTTGAAGC		
MGAS315	ACTAAACTTG TCCTTTTCAGT AGGTAAATCT CACCAAGACG AAGTTGAAGC		
SSI-1	ACTAAACTTG TCCTTTTCAGT AGGTAAATCT CACCAAGACG AAGTTGAAGC		
Manfredo	ACTAAACTTG TCCTTTTCAGT AGGTAAATCT CACCAAGACG AAGTTGAAGC		
MGAS8232	ACTAAACTTG TCCTTTTCAGT AGGTAAATCT CACCAAGACG AAGTTGAAGC		
	351		400
ATCC700294	TCCAGAAGGA ATTACTTTCA CTGTTGCTAA CCCAACTTCA ATCTCAGTTG		
MGAS315	TCCAGAAGGA ATTACTTTCA CTGTTGCTAA CCCAACTTCA ATCTCAGTTG		
SSI-1	TCCAGAAGGA ATTACTTTCA CTGTTGCTAA CCCAACTTCA ATCTCAGTTG		
Manfredo	TCCAGAAGGA ATTACTTTCA CTGTTGCTAA CCCAACTTCA ATCTCAGTTG		
MGAS8232	TCCAGAAGGA ATTACTTTCA CTGTTGCTAA CCCAACTTCA ATCTCAGTTG		

Figure 31 (continued)

	401		450
ATCC700294	AAGGAATCAA CAAAGAAGTT GTTGGTCAAA CAGCTGCTTA CATCCGTAGC		
MGAS315	AAGGAATCAA CAAAGAAGTT GTTGGTCAAA CAGCTGCTTA CATCCGTAGC		
SSI-1	AAGGAATCAA CAAAGAAGTT GTTGGTCAAA CAGCTGCTTA CATCCGTAGC		
Manfredo	AAGGAATCAA CAAAGAAGTT GTTGGTCAAA CAGCTGCTTA CATCCGTAGC		
MGAS8232	AAGGAATCAA CAAAGAAGTT GTTGGTCAAA CAGCTGCTTA CATCCGTAGC		
	451		500
ATCC700294	TTGCGTTCAC CAGAGCCTTA CAAAGGCAAA GGGATCCGTT ACGTTGGTGA		
MGAS315	TTGCGTTCAC CAGAGCCTTA CAAAGGCAAA GGGATCCGTT ACGTTGGTGA		
SSI-1	TTGCGTTCAC CAGAGCCTTA CAAAGGCAAA GGGATCCGTT ACGTTGGTGA		
Manfredo	TTGCGTTCAC CAGAGCCTTA CAAAGGCAAA GGGATCCGTT ACGTTGGTGA		
MGAS8232	TTGCGTTCAC CAGAGCCTTA CAAAGGCAAA GGGATCCGTT ACGTTGGTGA		
	501		537
ATCC700294	ATACGTACGC CTTAAAGAAG GTAAAACAGG TAAATAA		
MGAS315	ATACGTACGC CTTAAAGAAG GTAAAACAGG TAAATAA		
SSI-1	ATACGTACGC CTTAAAGAAG GTAAAACAGG TAAATAA		
Manfredo	ATACGTACGC CTTAAAGAAG GTAAAACAGG TAAATAA		
MGAS8232	ATACGTACGC CTTAAAGAAG GTAAAACAGG TAAATAA		

Figure 32

	1		50
ATCC700294	MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI		
MGAS315	MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI		
SSI-1	MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI		
Manfredo	MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI		
MGAS8232	MSRIGNKVIT MPAGVELTNN NNVITVKGPK GELTREFNKN IEIKVEGTEI		
	51		100
ATCC700294	TVVRPNDSKE MKTIHGTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG		
MGAS315	TVVRPNDSKE MKTIHGTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG		
SSI-1	TVVRPNDSKE MKTIHGTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG		
Manfredo	TVVRPNDSKE MKTIHGTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG		
MGAS8232	TVVRPNDSKE MKTIHGTTRA NLNNMVVGVS EGFKKDLEMK GVGYRAQLQG		
	101		150
ATCC700294	TKLVLSVGKS HQDEVEAPEG ITFTVANPTS ISVEGINKEV VGQTAAYIRS		
MGAS315	TKLVLSVGKS HQDEVEAPEG ITFTVANPTS ISVEGINKEV VGQTAAYIRS		
SSI-1	TKLVLSVGKS HQDEVEAPEG ITFTVANPTS ISVEGINKEV VGQTAAYIRS		
Manfredo	TKLVLSVGKS HQDEVEAPEG ITFTVANPTS ISVEGINKEV VGQTAAYIRS		
MGAS8232	TKLVLSVGKS HQDEVEAPEG ITFTVANPTS ISVEGINKEV VGQTAAYIRS		
	151		178
ATCC700294	LRSPEPYKGK GIRYVGEYVR LKEGKTGK		
MGAS315	LRSPEPYKGK GIRYVGEYVR LKEGKTGK		
SSI-1	LRSPEPYKGK GIRYVGEYVR LKEGKTGK		
Manfredo	LRSPEPYKGK GIRYVGEYVR LKEGKTGK		
MGAS8232	LRSPEPYKGK GIRYVGEYVR LKEGKTGK		

Figure 33

	1		50
ATCC700294	ATGTTTCAGT	TAAGAAAAAA	AATGACGCGC AAACAATTAG CCTTGTTGAG
MGAS315	ATGTTTCAGT	TAAGAAAAAA	AATGACGCGC AAACAATTAG CCTTGTTGAG
SSI-1	ATGTTTCAGT	TAAGAAAAAA	AATGACGCGC AAACAATTAG CCTTGTTGAG
Manfredo	ATGTTTCAGT	TAAGAAAAAA	AATGACGCGC AAACAATTAG CCTTGTTGAG
MGAS8232	ATGTTTCAGT	TAAGAAAAAA	AATGACGCGC AAACAATTAG CCTTGTTGAG
	51		100
ATCC700294	TGCTGGAGTG	TTGACCTGTG	TGGTTGGTGG TAGCTACTTG ATAATGAACC
MGAS315	TGCTGGAGTG	TTGACCTGTG	TGGTTGGTGG TAGCTACTTG ATAATGAACC
SSI-1	TGCTGGAGTG	TTGACCTGTG	TGGTTGGTGG TAGCTACTTG ATAATGAACC
Manfredo	TGCTGGAGTG	TTGACCTGTG	TGGTTGGTGG TAGCTACTTG ATAATGAACC
MGAS8232	TGCTGGAGTG	TTGACCTGTG	TGGTTGGTGG TACCTACTTG ATAATGAATC
	101		150
ATCC700294	ATCAACAACA	AGAAATTGTC	TCTAGTGTCA ACAAAGTAAA AGCCTTAACC
MGAS315	ATCAACAACA	AGAAATTGTC	TCTAGTGTCA ACAAAGTAAA AGCCTTAACC
SSI-1	ATCAACAACA	AGAAATTGTC	TCTAGTGTCA ACAAAGTAAA AGCCTTAACC
Manfredo	ATCAACAACA	AGAAATTGTC	TCTAGTGTCA ACAAAGTAAA AGCCTTAACC
MGAS8232	ATCAACAACA	AGAAATTGTC	TCTAGTGTCA ACAAAGTAAA AGCCTTAACC
	151		200
ATCC700294	ATAAAAGAAG	CCATGGAACA	AGGAAAAGAT ATCAGCTTGA CCTTAGCTGG
MGAS315	ATAAAAGAAG	CCATGGAACA	AGGAAAAGAT ATCAGCTTGA CCTTAGCTGG
SSI-1	ATAAAAGAAG	CCATGGAACA	AGGAAAAGAT ATCAGCTTGA CCTTAGCTGG
Manfredo	ATAAAAGAAG	CCATGGAACA	AGGAAAAGAT ATCAGCTTGA CCTTAGCTGG
MGAS8232	ATAAAAGAAG	CCATGGAACA	AGGAAAAGAT ATCAGCTTGA CCTTAGCTGG
	201		250
ATCC700294	CGAAGTAACA	GCTAACAACA	GCAGCAAAGT CAAAATCGAC TCAAGTAAAG
MGAS315	CGAAGTAACA	GCTAACAACA	GCAGCAAAGT CAAAATCGAC TCAAGTAAAG
SSI-1	CGAAGTAACA	GCTAACAACA	GCAGCAAAGT CAAAATCGAC TCAAGTAAAG
Manfredo	CGAAGTAACA	GCTAACAACA	GCAGCAAAGT CAAAATCGAC TCAAGTAAAG
MGAS8232	CGAAGTAACA	GCTAACAACA	GCAGCAAAGT CAAAATCGAC TCAAGTAAAG
	251		300
ATCC700294	GAGAAGTCAA	AGAGGTCTTT	GTTAAAAAAG GCGATGTTGT CAAAGTAGGA
MGAS315	GAGAAGTCAA	AGAGGTCTTT	GTTAAAAAAG GCGATGTTGT CAAAGTAGGA
SSI-1	GAGAAGTCAA	AGAGGTCTTT	GTTAAAAAAG GCGATGTTGT CAAAGTAGGA
Manfredo	GAGAAGTCAA	AGAGGTCTTT	GTTAAAAAAG GCGATGTTGT CAAAGTAGGA
MGAS8232	GAGAAGTCAA	AGATGTCTTT	GTTAAAAAAG GCGATGTTGT CAAAGTAGGA
	301		350
ATCC700294	CAACCCTTGT	TTAGCTATGA	AACGTCACAG CGGTTAACGG CTCAAAGTTC
MGAS315	CAACCCTTGT	TTAGCTATGA	AACGTCACAG CGGTTAACGG CTCAAAGTTC
SSI-1	CAACCCTTGT	TTAGCTATGA	AACGTCACAG CGGTTAACGG CTCAAAGTTC
Manfredo	CAACCCTTGT	TTAGCTATGA	AACGTCACAG CGGTTAACGG CTCAAAGTTC
MGAS8232	CAACCCTTGT	TTAGCTATGA	AACGTCACAA CGGTTAACGG CTCAAAGTTC
	351		400
ATCC700294	AGAATTTGAT	GTTCAAACCA	AAGCCAATCA GCTCCAAGTT GCTAAAACCA
MGAS315	AGAATTTGAT	GTTCAAACCA	AAGCCAATCA GCTCCAAGTT GCTAAAACCA
SSI-1	AGAATTTGAT	GTTCAAACCA	AAGCCAATCA GCTCCAAGTT GCTAAAACCA
Manfredo	AGAATTTGAT	GTTCAAACCA	AAGCCAATCA ACTCCAAGTT GCTAAAACCA
MGAS8232	AGAATTTGAT	GTTCAAACCA	AAGCCAATCA ACTCCAAGTT GCTAAAACCA

Figure 33 (continued)

	401				450
ATCC700294	ATGCAGCATT	GAAGTGGGAA	ACCTACAATC	GCAAGGTCAA	TGAAATCAAC
MGAS315	ATGCAGCATT	GAAGTGGGAA	ACCTACAATC	GCAAGGTCAA	TGAAATCAAC
SSI-1	ATGCAGCATT	GAAGTGGGAA	ACCTACAATC	GCAAGGTCAA	TGAAATCAAC
Manfredo	ATGCAGCATT	GAAGTGGGAA	ACCTACAATC	GCAAGGTCAA	TGAAATCAAC
MGAS8232	ATGCAGCATT	GAAGTGGGAA	ACCTACAATC	GCAAGGTCAA	TGAAATCAAT
	451				500
ATCC700294	ACCCTAAAAT	CTCGCTACAA	CACTGCACCA	GATGAGAGCT	TACTAGAGCA
MGAS315	ACCCTAAAAT	CTCGCTACAA	CACTGCACCA	GATGAGAGCT	TACTAGAGCA
SSI-1	ACCCTAAAAT	CTCGCTACAA	CACTGCACCA	GATGAGAGCT	TACTAGAGCA
Manfredo	ACCCTAAAAT	CTCGCTACAA	CACTGCACCA	GATGAGAGCT	TACTAGAGCA
MGAS8232	ACCCTAAAAT	CTCGCTACAA	CACTGCACCA	GATGAGAGCT	TACTAGAGCA
	501				550
ATCC700294	AATTCGCAGC	GCAGAAGACA	GTGTATCCCA	AGCACTAAGC	GATGCCAAAA
MGAS315	AATTCGCAGC	GCAGAAGACA	GTGTATCCCA	AGCACTAAGC	GATGCCAAAA
SSI-1	AATTCGCAGC	GCAGAAGACA	GTGTATCCCA	AGCACTAAGC	GATGCCAAAA
Manfredo	AATTCGCAGC	GCAGAAGACA	GTGTATCCCA	AGCACTAAGC	GATGCCAAAA
MGAS8232	AATTCGCAGC	GCAGAAGACA	GTGTATCTCA	AGCACTAAGC	GATGCCAAAA
	551				600
ATCC700294	CAGCAGATAG	CGATGTCAAA	ACCGCTCAAA	TCGAACTCGA	TAAAGCTAAT
MGAS315	CAGCAGATAG	CGATGTCAAA	ACCGCTCAAA	TCGAACTCGA	TAAAGCTAAT
SSI-1	CAGCAGATAG	CGATGTCAAA	ACCGCTCAAA	TCGAACTCGA	TAAAGCTAAT
Manfredo	CAGCAGATAG	CGATGTCAAA	ACCGCTCAAA	TCGAACTCGA	TAAAGCTAAT
MGAS8232	CAGCAGATAG	CGATGTCAAA	ACCGCTCAAA	TCGAACTCGA	TAAAGCTAAT
	601				650
ATCC700294	GCTACTGCCA	CAACGGAAAA	AGGTAAACTA	GAGTATGACA	CCGTTAAGTC
MGAS315	GCTACTGCCA	CAACGGAAAA	AGGTAAACTA	GAGTATGACA	CCGTTAAGTC
SSI-1	GCTACTGCCA	CAACGGAAAA	AGGTAAACTA	GAGTATGACA	CCGTTAAGTC
Manfredo	GCTACTGCCA	CAATGGAAAA	AGGTAAACTA	GAGTATGACA	CCGTTAAGTC
MGAS8232	GCTACTGCCG	CAACGGAAAA	AGGTAAACTA	GAGTATGACA	CCGTTAAGTC
	651				700
ATCC700294	AGACACCGCA	GGAACCAT TG	TTAGTCTAAA	TACTGATTTG	CCAAATCAAT
MGAS315	AGACACCGCA	GGAACCAT TG	TTAGTCTAAA	TACTGATTTG	CCAAATCAAT
SSI-1	AGACACCGCA	GGAACCAT TG	TTAGTCTAAA	TACTGATTTG	CCAAATCAAT
Manfredo	AGACACCGCA	GGAACCAT TG	TTAGCCTAAA	TACTGATTTG	CCAAATCAAT
MGAS8232	AGACACCGCA	GGAACCAT TG	TTAGTCTAAA	TACTGATTTG	CCAAATCAAT
	701				750
ATCC700294	CAAAATCCAA	AAAAGAAAAAT	GAAACTTTTA	TGGAAATTAT	CGACAAATCA
MGAS315	CAAAATCCAA	AAAAGAAAAAT	GAAACTTTTA	TGGAAATTAT	CGACAAATCA
SSI-1	CAAAATCCAA	AAAAGAAAAAT	GAAACTTTTA	TGGAAATTAT	CGACAAATCA
Manfredo	CAAAATCCAA	AAAAGAAAAAT	GAAACTTTTA	TGGAAATTAT	CGACAAATCA
MGAS8232	CAAAATCCAA	AAAAGAAAAAT	GAAACTTTTA	TGGAAATTAT	CGACAAATCA
	751				800
ATCC700294	AAAATGTTAG	TCAAAGGTAA	CATTAGTGAA	TTTGACCGTG	ACAAGTTAAA
MGAS315	AAAATGTTAG	TCAAAGGTAA	CATTAGTGAA	TTTGACCGTG	ACAAGTTAAA
SSI-1	AAAATGTTAG	TCAAAGGTAA	CATTAGTGAA	TTTGACCGTG	ACAAGTTAAA
Manfredo	AAAATGTTAG	TCAAAGGTAA	CATCAGTGAA	TTTGACCGTG	ACAAGTTAAA
MGAS8232	AAAATGTTAG	TCAAAGGTAA	CATCAGTGAA	TTTGACCGTG	ACAAGTTAAA

Figure 33 (continued)

	801		850
ATCC700294	AATCGGTCAA AAAGTCGAAG TGATTGACCG CAAAGACAAC TCTAAAAAAT		
MGAS315	AATCGGTCAA AAAGTCGAAG TGATTGACCG CAAAGACAAC TCTAAAAAAT		
SSI-1	AATCGGTCAA AAAGTCGAAG TGATTGACCG CAAAGACAAC TCTAAAAAAT		
Manfredo	AATCGATCAA AAAGTCGAAG TGATTGACCG CAAAGACAAC TCTAAAAAAT		
MGAS8232	AATCGATCAA AAAGTCGAAG TGATTGACCG CAAAGACAAC TCTAAAAAAT		
	851		900
ATCC700294	GGACTGGAAA AGTAACCCAA GTTGGCAACC TCAAAGCAGA GGAAAAAGGC		
MGAS315	GGACTGGAAA AGTAACCCAA GTTGGCAACC TCAAAGCAGA GGAAAAAGGC		
SSI-1	GGACTGGAAA AGTAACCCAA GTTGGCAACC TCAAAGCAGA GGAAAAAGGC		
Manfredo	GGACTGGAAA AGTAACCCAA GTTGGCAACC TCAAAGCAGA GGAAAAAGGC		
MGAS8232	GGACTGGAAA AGTAACCCAA GTTGGCAACC TCAAAGCAGA GGAAAAAGGC		
	901		950
ATCC700294	CAAGGTCAAG GCCAAGGTGG CAATGACCAA CAAGATAATC CAAACCAAGC		
MGAS315	CAAGGTCAAG GCCAAGGTGG CAATGACCAA CAAGATAATC CAAACCAAGC		
SSI-1	CAAGGTCAAG GCCAAGGTGG CAATGACCAA CAAGATAATC CAAACCAAGC		
Manfredo	CAAGGTCAAG GCCAAGGTGG CAATGACCAA CAAGACAATC CAAACCAAGC		
MGAS8232	CAAGGTCAAG GCCAAGGTGG CAATGACCAA CAAGATAATC CAAACCAAGC		
	951		1000
ATCC700294	AAAATTC CCT TATGTTATTG AACTTGACCA ATCAGACAAG CAGCCACTCA		
MGAS315	AAAATTC CCT TATGTTATTG AACTTGACCA ATCAGACAAG CAGCCACTCA		
SSI-1	AAAATTC CCT TATGTTATTG AACTTGACCA ATCAGACAAG CAGCCACTCA		
Manfredo	AAAATTC CCT TATGTTATCG AACTTGACCA ATCAGACAAG CAGCCACTCA		
MGAS8232	AAAATTC CCT TATGTTATCG AACTTGACCA ATCAGACAAG CAGCCACTCA		
	1001		1050
ATCC700294	TTGGCTCACA CACCTATGTT AATGTGCTCA ACAATGTTCC AGAAGCTGGC		
MGAS315	TTGGCTCACA CACCTATGTT AATGTACTCA ACAATGTTCC AGAAGCTGGC		
SSI-1	TTGGCTCACA CACCTATGTT AATGTACTCA ACAATGTTCC AGAAGCTGGC		
Manfredo	TTGGCTCACA CACCTATGTT AATGTGCTCA ACAATGTTCC AGAAGCTGGC		
MGAS8232	TTGGTTCACA CACCTATGTT AATGTGCTCA ACAATGTTCC AGAAGCTGGC		
	1051		1100
ATCC700294	AAGATCGTAT TGAAAGAAAC CTTTACAATG GCAGAAAATG GAAAAACCTA		
MGAS315	AAGATCGTAT TGAAAGAAAC CTTTACAATG GCAGAAAATG GAAAAACCTA		
SSI-1	AAGATCGTAT TGAAAGAAAC CTTTACAATG GCAGAAAATG GAAAAACCTA		
Manfredo	AAGATCGTAT TGAAAGAAAC CTTTACAATG GCAGAAAATG GAAAAACCTA		
MGAS8232	AAGATCGTAT TGAAAGAAAC CTTTACAATG GCAGAAAATG GAAAAACCTA		
	1101		1150
ATCC700294	TGTGTGGAAA GTTGATAAAA ACAAGGTCAA AAAACAAGAA ATCAAGACTA		
MGAS315	TGTGTGGAAA GTTGATAAAA ACAAGGTCAA AAAACAAGAA ATCAAGACTA		
SSI-1	TGTGTGGAAA GTTGATAAAA ACAAGGTCAA AAAACAAGAA ATCAAGACTA		
Manfredo	TGTGTGGAAA GTTGATAAAA ACAAGGTCAA AAAACAAGAA ATCAAGACTA		
MGAS8232	TGTGTGGAAA GTTGATAAAA ACAAGGTCAA AAAACAAGAA ATCAAGACTA		
	1151		1200
Manfredo	AGCCCTTCTC AAAAGGTTAT GTTGAGGTAA CAAGTGGCTT GACTATGCAA		
MGAS315	AGCCCTTCTC AAAAGGTTAT GTTGAGGTAA CAAGTGGCTT GACTATGCAA		
SSI-1	AGCCCTTCTC AAAAGGTTAT GTTGAGGTAA CAAGTGGCTT GACTATGCAA		
Manfredo	AGCCCTTCTC AAAAGGTTAT GTTGAGGTGA CAAGTGGCTT GACTATGCAA		
MGAS8232	AGCCCTTCTC AAAAGGTTAT GTTGAGGTGA CAAGCGGCTT GACTATGCAA		

Figure 33 (continued)

	1201		1250
ATCC700294	GATAAGATTG CTCAGCCGCT TCCTGGCATG AAAGACGGTA TGGAGGTAGG		
MGAS315	GATAAGATTG CTCAGCCGCT TCCTGGCATG AAAGACGGTA TGGAGGTAGG		
SSI-1	GATAAGATTG CTCAGCCGCT TCCTGGCATG AAAGACGGTA TGGAGGTAGG		
Manfredo	GATAAGATTG CTCAGCCGCT TCCTGGCATG AAAGACGGTA TGGAGGTAGG		
MGAS8232	GATAAGATTG CTCAGCCGCT TCCTGGCATG AAAGACGGTA TGGAGGTAGG		
	1251	1269	
ATCC700294	AAGTATTGTT AAACCTTAA		
MGAS315	AAGTATTGTT AAACCTTAA		
SSI-1	AAGTATTGTT AAACCTTAA		
Manfredo	AAGTATTGTT AAACCTTAA		
MGAS8232	AAGTATTGTT AAACCTTAA		

Figure 34

	1		50
ATCC700294	MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEIV SSVNKKV KALT		
MGAS315	MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEIV SSVNKKV KALT		
SSI-1	MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEIV SSVNKKV KALT		
Manfredo	MFQLRKKMTR KQLALLSAGV LTCVVGGSYL IMNHQQQEIV SSVNKKV KALT		
MGAS8232	MFQLRKKMTR KQLALLSAGV LTCVVGGTYL IMNHQQQEIV SSVNKKV KALT		
	51		100
ATCC700294	IKEAMEQGKD ISLTLAGEVT ANNSSKVKID SSKGEVKEVF VKKGDVVKVG		
MGAS315	IKEAMEQGKD ISLTLAGEVT ANNSSKVKID SSKGEVKEVF VKKGDVVKVG		
SSI-1	IKEAMEQGKD ISLTLAGEVT ANNSSKVKID SSKGEVKEVF VKKGDVVKVG		
Manfredo	IKEAMEQGKD ISLTLAGEVT ANNSSKVKID SSKGEVKEVF VKKGDVVKVG		
MGAS8232	IKEAMEQGKD ISLTLAGEVT ANNSSKVKID SSKGEVKDVF VKKGDVVKVG		
	101		150
ATCC700294	QPLFSYETSQ RLTAQSSEFD VQTKANQLQV AKTNAALKWE TYNRKVNEIN		
MGAS315	QPLFSYETSQ RLTAQSSEFD VQTKANQLQV AKTNAALKWE TYNRKVNEIN		
SSI-1	QPLFSYETSQ RLTAQSSEFD VQTKANQLQV AKTNAALKWE TYNRKVNEIN		
Manfredo	QPLFSYETSQ RLTAQSSEFD VQTKANQLQV AKTNAALKWE TYNRKVNEIN		
MGAS8232	QPLFSYETSQ RLTAQSSEFD VQTKANQLQV AKTNAALKWE TYNRKVNEIN		
	151		200
ATCC700294	TLKSRYNTAP DESLLEQIRS AEDSVSQALS DAKTADSDVK TAQIELDKAN		
MGAS315	TLKSRYNTAP DESLLEQIRS AEDSVSQALS DAKTADSDVK TAQIELDKAN		
SSI-1	TLKSRYNTAP DESLLEQIRS AEDSVSQALS DAKTADSDVK TAQIELDKAN		
Manfredo	TLKSRYNTAP DESLLEQIRS AEDSVSQALS DAKTADSDVK TAQIELDKAN		
MGAS8232	TLKSRYNTAP DESLLEQIRS AEDSVSQALS DAKTADSDVK TAQIELDKAN		
	201		250
ATCC700294	ATATTEKGKL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN ETFMEIIDKS		
MGAS315	ATATTEKGKL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN ETFMEIIDKS		
SSI-1	ATATTEKGKL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN ETFMEIIDKS		
Manfredo	ATATMEKGKL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN ETFMEIIDKS		
MGAS8232	ATAATEKGKL EYDTVKSDTA GTIVSLNTDL PNQSKSKKEN ETFMEIIDKS		
	251		300
ATCC700294	KMLVKGNISE FDRDKLKIGQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG		
MGAS315	KMLVKGNISE FDRDKLKIGQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG		
SSI-1	KMLVKGNISE FDRDKLKIGQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG		
Manfredo	KMLVKGNISE FDRDKLKIDQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG		
MGAS8232	KMLVKGNISE FDRDKLKIDQ KVEVIDRKDN SKKWTGKVTQ VGNLKAEEKG		

Figure 34 (continued)

	301				350
ATCC700294	QGQGQGGNDQ	QDNPNQAKFP	YVIELDQSDK	QPLIGSHTYV	NVLNNVPEAG
MGAS315	QGQGQGGNDQ	QDNPNQAKFP	YVIELDQSDK	QPLIGSHTYV	NVLNNVPEAG
SSI-1	QGQGQGGNDQ	QDNPNQAKFP	YVIELDQSDK	QPLIGSHTYV	NVLNNVPEAG
Manfredo	QGQGQGGNDQ	QDNPNQAKFP	YVIELDQSDK	QPLIGSHTYV	NVLNNVPEAG
MGAS8232	QGQGQGGNDQ	QDNPNQAKFP	YVIELDQSDK	QPLIGSHTYV	NVLNNVPEAG
	351				400
ATCC700294	KIVLKETFTM	AENGKTYVWK	VDKNKVKKQE	IKTKPFSSKY	VEVTSGLTMQ
MGAS315	KIVLKETFTM	AENGKTYVWK	VDKNKVKKQE	IKTKPFSSKY	VEVTSGLTMQ
SSI-1	KIVLKETFTM	AENGKTYVWK	VDKNKVKKQE	IKTKPFSSKY	VEVTSGLTMQ
Manfredo	KIVLKETFTM	AENGKTYVWK	VDKNKVKKQE	IKTKPFSSKY	VEVTSGLTMQ
MGAS8232	KIVLKETFTM	AENGKTYVWK	VDKNKVKKQE	IKTKPFSSKY	VEVTSGLTMQ
	401		422		
ATCC700294	DKIAQPLPGM	KDGMEVGSIV	KP		
MGAS315	DKIAQPLPGM	KDGMEVGSIV	KP		
SSI-1	DKIAQPLPGM	KDGMEVGSIV	KP		
Manfredo	DKIAQPLPGM	KDGMEVGSIV	KP		
MGAS8232	DKIAQPLPGM	KDGMEVGSIV	KP		

Figure 35

	1				50
ATCC700294	ATGATAAAAC	GATGTAAAGG	AATTGGTCTA	GCCTTAATGG	CCTTCTTTTT
MGAS315	ATGATAAAAC	GATGTAAAGG	AATTGGTCTA	GTCTTAATGG	CCTTCTTTTT
SSI-1	ATGATAAAAC	GATGTAAAGG	AATTGGTCTA	GTCTTAATGG	CCTTCTTTTT
Manfredo	ATGATAAAAC	GATGTAAAGG	AATTGGTCTA	GCCTTAATGG	CCTTCTTTTT
MGAS8232	ATGATAAAAC	GATGTAAAGG	AATTGGTCTA	GTCTTAATGG	CCTTCTTTTT
	51				100
ATCC700294	GGTAGCTTGT	GTGAATCAGC	ACCCATAAAC	GGCTAAAGAG	ACTGAACAGC
MGAS315	GGTAGCTTGT	GTGAATCAGC	ACCCATAAAC	GGCTAAAGAG	ACTGAACAGC
SSI-1	GGTAGCTTGT	GTGAATCAGC	ACCCATAAAC	GGCTAAAGAG	ACTGAACAGC
Manfredo	GGTAGCTTGT	GTGAATCAGC	ACCCATAAAC	GGCTAAAGAG	ACTGAACAGC
MGAS8232	GGTAGCTTGT	GTGAATCAGC	ACCCATAAAC	GGCTAAAGAG	ACTGAACAGC
	101				150
ATCC700294	AGAGAATTGT	AGCCACTTCG	GTTGCTGTGG	TTGATATCTG	TGACCGTTTA
MGAS315	AGAGAATTGT	AGCCACTTCG	GTTGCTGTGG	TTGATATCTG	TGACCGTTTA
SSI-1	AGAGAATTGT	AGCCACTTCG	GTTGCTGTGG	TTGATATCTG	TGACCGTTTA
Manfredo	AGAGAATTGT	AGCCACTTCG	GTTGCTGTGG	TTGATATCTG	TGACCGTTTA
MGAS8232	AGAGAATTGT	AGCCACTTCG	GTTGCTGTGG	TTGATATCTG	TGACCGTTTA
	151				200
ATCC700294	AATTTAGACC	TCGTTGGGGT	TTGTGATAGT	AAATTATATA	CCCTTCCTAA
MGAS315	AATTTAGACC	TCGTTGGGGT	TTGTGATAGT	AAATTATATA	CCCTTCCTAA
SSI-1	AATTTAGACC	TCGTTGGGGT	TTGTGATAGT	AAATTATATA	CCCTTCCTAA
Manfredo	AATTTAGACC	TCGTTGGGGT	TTGTGATAGT	AAATTATATA	CCCTTCCTAA
MGAS8232	AATTTAGACC	TCGTTGGGGT	TTGTGATAGT	AAATTATATA	CCCTTCCTAA
	201				250
ATCC700294	ACGCTATGAT	GCTGTTAAGC	GTGTGGGTTT	ACCCATGAAT	CCTGATATAG
MGAS315	ACGCTATGAT	GCTGTTAAGC	GTGTGGGTTT	ACCCATGAAT	CCTGATATAG
SSI-1	ACGCTATGAT	GCTGTTAAGC	GTGTGGGTTT	ACCCATGAAT	CCTGATATAG
Manfredo	ACGCTATGAT	GCTGTTAAGC	GTGTGGGTTT	ACCCATGAAT	CCTGATATAG
MGAS8232	ACGCTATGAT	GCTGTTAAGC	GTGTGGGTTT	ACCCATGAAT	CCTGATATAG

Figure 35 (continued)

	651				700
ATCC700294	GGCTAAGGAG	CCTGACTTGA	TTTTACGAAC	AGCTCATGCC	ATTCCAGACA
MGAS315	AGCTAAGGAG	CCTGACTTGA	TTTTACGAAC	AGCTCACGCC	ATTCCAGACA
SSI-1	AGCTAAGGAG	CCTGACTTGA	TTTTACGAAC	AGCTCACGCC	ATTCCAGACA
Manfredo	GGCTAAGGAG	CCTGATTGGA	TTTTACGAAC	AGCTCACGCC	ATTCCAGACA
MGAS8232	AGCTAAGGAG	CCTGACTTGA	TTTTACGAAC	AGCTCACGCC	ATTCCAGACA
	701				750
ATCC700294	AGGTAAAAGT	GATGTTTGAC	AAAGAATTTG	CTGAAAATGA	TATTTGGAAA
MGAS315	AGGTAAAAGT	GATGTTTGAC	AAAGAATTTG	CTGAAAATGA	TATTTGGAAA
SSI-1	AGGTAAAAGT	GATGTTTGAC	AAAGAATTTG	CTGAAAATGA	TATTTGGAAA
Manfredo	AGGTAAAAGT	GATGTTTGAC	AAAGAATTTG	CTGAAAATGA	TATTTGGAAA
MGAS8232	AGGTAAAAGT	GATGTTTGAC	AAAGAATTTG	CTGAAAATGA	TATTTGGAAA
	751				800
ATCC700294	CATTTTACGG	CAGTCAAGGA	AGGGAAAGTC	TATGATTTGG	ACAATACCCT
MGAS315	CATTTTACGG	CAGTCAAGGA	AGGGAAAGTC	TATGATTTGG	ACAATACCCT
SSI-1	CATTTTACGG	CAGTCAAGGA	AGGGAAAGTC	TATGATTTGG	ACAATACCCT
Manfredo	CATTTTACGG	CAGTCAAGGA	AGGGAAAGTC	TATGATTTGG	ACAATACCCT
MGAS8232	CATTTTACGG	CAGTCAAGGA	AGGGAAAGTC	TATGATTTGG	ACAATACCCT
	801				850
ATCC700294	GTTTGGCATG	AGTGCTAAAT	TGAACTACCC	AGAAGCCTTG	GACACCTTAA
MGAS315	GTTTGGCATG	AGTGCTAAAT	TGAACTACCC	AGAAGCCTTG	GACACCTTAA
SSI-1	GTTTGGCATG	AGTGCTAAAT	TGAACTACCC	AGAAGCCTTG	GACACCTTAA
Manfredo	GTTTGGCATG	AGTGCTAAAT	TGAACTACCC	AGAAGCCTTG	GACACCTTAA
MGAS8232	GTTTGGCATG	AGTGCTAAAT	TGAACTACCC	AGAAGCCTTG	GACACCTTAA
	851			885	
ATCC700294	CACAGCTTTT	TGACCACGTG	GGAGATCATC	CGTAA	
MGAS315	CACAGCTTTT	TGACCACGTG	GGAGATCATC	CGTAA	
SSI-1	CACAGCTTTT	TGACCACGTG	GGAGATCATC	CGTAA	
Manfredo	CACAGCTTTT	TGACCGCGTG	GGAGATCATC	CGTAA	
MGAS8232	CACAGCTTTT	TGACCACGTG	GGAGATCATC	CGTAA	

Figure 36

	1				50
ATCC700294	MIKRCKGIGL	ALMAFFLVAC	VNQHPKTAKE	TEQQRIVATS	VAVVDICDRL
MGAS315	MIKRCKGIGL	VLMAFFLVAC	VNQHPKTAKE	TEQQRIVATS	VAVVDICDRL
SSI-1	MIKRCKGIGL	VLMAFFLVAC	VNQHPKTAKE	TEQQRIVATS	VAVVDICDRL
Manfredo	MIKRCKGIGL	ALMAFFLVAC	VNQHPKTAKE	TEQQRIVATS	VAVVDICDRL
MGAS8232	MIKRCKGIGL	VLMAFFLVAC	VNQHPKTAKE	TEQQRIVATS	VAVVDICDRL
	51				100
ATCC700294	NLDLVGVCDs	KLYTLPKRYD	AVKRVGLPMN	PDIELIASLK	PTWILSPNSL
MGAS315	NLDLVGVCDs	KLYTLPKRYD	AVKRVGLPMN	PDIELIASLK	PTWILSPNSL
SSI-1	NLDLVGVCDs	KLYTLPKRYD	AVKRVGLPMN	PDIELIASLK	PTWILSPNSL
Manfredo	NLDLVGVCDs	KLYTLPKRYD	AVKRVGLPMN	PDIELIASLK	PTWILSPNSL
MGAS8232	NLDLVGVCDs	KLYTLPKRYD	AVKRVGLPMN	PDIELIASLK	PTWILSPNSL
	101				150
ATCC700294	QEDLEPKYQK	LDTEYGFLNL	RSVEGMYQSI	DDLGNLFQRQ	QEAKELRQQY
MGAS315	QEDLEPKYQK	LDTEYGFLNL	RSVEGMYQSI	DDLGNLFQRQ	QEAKELRQQY
SSI-1	QEDLEPKYQK	LDTEYGFLNL	RSVEGMYQSI	DDLGNLFQRQ	QEAKELRQQY
Manfredo	QEDLEPKYQK	LDTEYGFLNL	RSVEGMYQSI	DDLGNLFQRQ	QEAKELRQQY
MGAS8232	QEDLEPKYQK	LDTEYGFLNL	RSVEGMYQSI	DDLGNLFQRQ	QEAKELRQQY

Figure 36 (continued)

	151				200
ATCC700294	QDY YRA FQAK	RKG KKKPKVL	ILMGLPGSYL	VATNQSYVGN	LLDLAGGENV
MGAS315	QDY YRA FQAK	RKG KKKPKVL	ILMGLPGSYL	VATNQSYVGN	LLDLAGGENV
SSI-1	QDY YRA FQAK	RKG KKKPKVL	ILMGLPGSYL	VATNQSYVGN	LLDLAGGENV
Manfredo	QDY YRA FQAK	RKG KKKPKVL	ILMGLPGSYL	VATNQSYVGN	LLDLAGGENV
MGAS8232	QDY YRA FQAK	RKG KKKPKVL	ILMGLPGSYL	VATNQSYVGN	LLDLAGGENV
	201				250
ATCC700294	YQSDEKEFLS	ANPEDMLAKE	PDLILRTAHA	IPDKVKVMFD	KEFAENDIWK
MGAS315	YQSDEKEFLS	VNPEDMLAKE	PDLILRTAHA	IPDKVKVMFD	KEFAENDIWK
SSI-1	YQSDEKEFLS	VNPEDMLAKE	PDLILRTAHA	IPDKVKVMFD	KEFAENDIWK
Manfredo	YQSDEKEFLS	ANPEDMLAKE	PDLILRTAHA	IPDKVKVMFD	KEFAENDIWK
MGAS8232	YQSDEKEFLS	VNPEDMLAKE	PDLILRTAHA	IPDKVKVMFD	KEFAENDIWK
	251				294
ATCC700294	HFTAVKEGKV	YDL DNTLFGM	SAKL NYPEAL	DTLTQLFDHV	GDHP
MGAS315	HFTAVKEGKV	YDL DNTLFGM	SAKL NYPEAL	DTLTQLFDHV	GDHP
SSI-1	HFTAVKEGKV	YDL DNTLFGM	SAKL NYPEAL	DTLTQLFDHV	GDHP
Manfredo	HFTAVKEGKV	YDL DNTLFGM	SAKL NYPEAL	DTLTQLFDRV	GDHP
MGAS8232	HFTAVKEGKV	YDL DNTLFGM	SAKL NYPEAL	DTLTQLFDHV	GDHP